tyrphostin a23 profile

tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2052
CHEMBL ID	76904
CHEBI ID	92862
SCHEMBL ID	241922
MeSH ID	M0168408

Synonym
CHEMBL76904
benzylidenemalononitrile (bmn) deriv. 23
bdbm4339
2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile
(3,4-dihydroxybenzylidene)malononitrile
cid_2052
MLS002153315
smr001230729
HMS3266E18
BRD-K49657628-001-03-1
BRD-K49657628-001-02-3
EU-0101160
tyrphostin 23, >=98%
NCGC00016043-01
tocris-0493
lopac-t-7165
NCGC00024615-01
HSCI1_000108
LOPAC0_001160
OPREA1_072726
BIOMOLKI2_000021
tyrphostin a23
ag 18
rg-50810
alpha-cyano-(3,4-dihydroxy)cinnamonitrile
NCGC00024615-04
rg 50810
(3,4-dihydroxyphenyl)methylene propanedinitrile
ag-18
propanedinitrile, ((3,4-dihydroxyphenyl)methylene)-
tyrphostin rg50810
tyrphostin ag18
tyrphostin 23 ,
BIOMOLKI_000011
NCGC00024615-02
NCGC00024615-03
NCGC00016043-03
SR-01000075506-6
3,4-(dihydroxybenzylidene)malononitrile
T 7165
NCGC00016043-07
EC-000.2086
118409-57-7
BMK1-B11
STL139213
(3,4-dihydroxybenzylidene)propanedinitrile
HMS3263H21
dtxsid9045215 ,
cas-118409-57-7
((3,4-dihydroxyphenyl)methylene)-propanedinitrile
dtxcid7025215
tox21_110287
AKOS005715658
rv0gcd31oj ,
unii-rv0gcd31oj
HMS2233I22
CCG-100615
NCGC00016043-04
NCGC00016043-05
NCGC00016043-06
NCGC00016043-02
HY-15644
CS-1387
FT-0675716
LP01160
S8009
propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-
HMS3369M02
((3,4-dihydroxyphenyl)methylene)-propenedinitrile
SCHEMBL241922
2-(3,4-dihydroxy-benzylidene)-malononitrile
VTJXFTPMFYAJJU-UHFFFAOYSA-N
3,4-dihydroxybenzylidene malononitrile
tox21_110287_1
NCGC00016043-08
T3503
NCGC00261845-01
tox21_501160
ag18
[(3,4-dihydroxyphenyl)methylene]-propenedinitrile
2-(3,4-dihydroxybenzylidene)malononitrile
AC-30286
mfcd00133899
J-003744
EX-A901
ag18;tyrphostin 23; rg-50810
tx 825
CHEBI:92862
HMS3653D19
AS-69033
tyrphostin-23
SR-01000075506-1
SR-01000075506-3
sr-01000075506
SW219523-1
BCP06838
Q27164614
ag 18 - cas 118409-57-7
ag 18 (tyrphostin 23)
HMS3678G15
HMS3414G15
BRD-K49657628-001-05-6
SDCCGSBI-0051127.P002
NCGC00016043-17
tyrphostin-ag-18
2-[(3,4-dihydroxyphenyl)methylene]-propanedinitrile
ag-18 (tyrphostin 23)
F6782-3631
tyrphostin 23;tyrphostin a23; rg-50810; ag 18

Class	Description
catechols	Any compound containing an o-diphenol component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	10.0000	0.0032	45.4673	12,589.2998	AID2517
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	79.4328	0.0447	17.8581	100.0000	AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	14.0919	0.1409	11.1940	39.8107	AID2451
Chain A, HADH2 protein	Homo sapiens (human)	Potency	20.9424	0.0251	20.2376	39.8107	AID886; AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	20.9424	0.0251	20.2376	39.8107	AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	3.9811	0.6310	35.7641	100.0000	AID504339
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	4.9693	0.1778	14.3909	39.8107	AID2147
endonuclease IV	Escherichia coli	Potency	17.7828	0.7079	12.4324	31.6228	AID1708
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	31.5914	0.1000	20.8793	79.4328	AID488773; AID588453
15-lipoxygenase, partial	Homo sapiens (human)	Potency	3.9811	0.0126	10.6917	88.5700	AID887
phosphopantetheinyl transferase	Bacillus subtilis	Potency	46.7187	0.1413	37.9142	100.0000	AID1490
USP1 protein, partial	Homo sapiens (human)	Potency	56.2341	0.0316	37.5844	354.8130	AID504865
NFKB1 protein, partial	Homo sapiens (human)	Potency	11.2202	0.0282	7.0559	15.8489	AID895; AID928
GLS protein	Homo sapiens (human)	Potency	4.1490	0.3548	7.9355	39.8107	AID624146; AID624170
TDP1 protein	Homo sapiens (human)	Potency	23.6052	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	7.9552	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	13.3042	0.1800	13.5574	39.8107	AID1460; AID1468
Thrombopoietin	Homo sapiens (human)	Potency	12.5893	0.0251	7.3048	31.6228	AID917; AID918
AR protein	Homo sapiens (human)	Potency	5.2548	0.0002	21.2231	8,912.5098	AID743035; AID743036; AID743063
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	1.4125	0.1000	22.9075	100.0000	AID485364
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	10.0000	0.7079	12.1943	39.8107	AID720542
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	14.5358	0.0112	12.4002	100.0000	AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	10.0000	0.0013	7.7625	44.6684	AID914; AID915
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	39.8107	0.0013	18.0743	39.8107	AID926; AID938
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	13.3332	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	9.4392	0.0010	22.6508	76.6163	AID1224838
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	18.8876	0.5318	15.4358	37.6858	AID504845
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	24.5454	0.0123	7.9835	43.2770	AID1645841
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	7.0795	0.2818	9.7212	35.4813	AID2326
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	30.3706	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	9.6238	0.0015	30.6073	15,848.9004	AID1224841; AID1259401
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	8.4769	0.0002	29.3054	16,493.5996	AID743075
cytochrome P450 2D6	Homo sapiens (human)	Potency	30.9008	0.0010	8.3798	61.1304	AID1645840
glucocerebrosidase	Homo sapiens (human)	Potency	19.9526	0.0126	8.1569	44.6684	AID2101
Parkin	Homo sapiens (human)	Potency	5.5620	0.8199	14.8306	44.6684	AID720572; AID720573
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	79.4328	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	13.4882	0.0355	20.9770	89.1251	AID504332
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	49.5203	0.0391	47.5451	146.8240	AID1224845; AID1224896
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	39.8107	0.5406	17.6392	96.1227	AID2364; AID2528
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	19.9526	0.0020	7.5337	39.8107	AID891
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	75.6863	23.9341	23.9341	23.9341	AID1967
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	15.8489	0.3162	12.4435	31.6228	AID902
polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)	Potency	15.8489	1.0000	12.2326	31.6228	AID1452
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	15.8489	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	19.7831	0.0063	6.9043	39.8107	AID883
D(1A) dopamine receptor	Homo sapiens (human)	Potency	2.3108	0.0224	5.9449	22.3872	AID488982
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	33.5521	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	53.7248	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	22.3872	0.0060	26.1688	89.1251	AID488953
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	125.8920	3.5481	19.5427	44.6684	AID743266
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0003	23.4451	159.6830	AID743065; AID743067
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	26.6032	0.0376	17.0823	61.1927	AID1259388
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	39.8107	0.0398	16.7842	39.8107	AID995
flap endonuclease 1	Homo sapiens (human)	Potency	18.8876	0.1337	25.4129	89.1251	AID488816; AID588795
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	26.6011	0.0006	27.2152	1,122.0200	AID743202
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	7.9433	0.1000	28.9256	213.3130	AID588591
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	46.0755	0.0501	27.0736	89.1251	AID588590
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	3.1623	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	3.1623	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	3.1623	0.1585	5.2879	12.5893	AID540303
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	18.3644	0.0079	8.2332	1,122.0200	AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform I	Homo sapiens (human)	Potency	22.3872	0.0752	15.2253	39.8107	AID485360
geminin	Homo sapiens (human)	Potency	0.5026	0.0046	11.3741	33.4983	AID624296; AID624297
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	10.6568	0.0316	22.3146	100.0000	AID588579
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	19.7312	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	31.6228	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	37.3017	0.1778	24.7352	79.4328	AID488949
lamin isoform A-delta10	Homo sapiens (human)	Potency	25.1189	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	12.5893	0.3162	12.7657	31.6228	AID881
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	17.9846	0.0063	8.2350	39.8107	AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	35.4813	1.9953	25.5327	50.1187	AID624288
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	14.2400	1.0000	10.4756	28.1838	AID1457; AID901
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	31.6228	1.0000	12.2248	31.6228	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	21.3497	0.0601	10.7453	37.9330	AID485367; AID485368; AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
alkaline phosphatase, intestinal	Homo sapiens (human)	IC50 (µMol)	100.0000	0.5650	12.9050	66.3000	AID488876
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein	Homo sapiens (human)	IC50 (µMol)	9.9700	0.1250	16.2603	74.8000	AID488906
intestinal alkaline phosphatase precursor	Mus musculus (house mouse)	IC50 (µMol)	4.2200	0.2590	11.8708	60.3000	AID488785
alkaline phosphatase, germ cell type preproprotein	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1100	11.3862	67.2000	AID488879
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	36.6667	0.0000	0.5369	10.0000	AID325790; AID69399; AID69555
Epidermal growth factor receptor	Homo sapiens (human)	Ki	11.0000	0.0000	0.2953	3.5000	AID1795632; AID69576
Aromatase	Homo sapiens (human)	IC50 (µMol)	70.6000	0.0000	1.2904	10.0000	AID429611
G1/S-specific cyclin-E1	Homo sapiens (human)	Ki	0.6166	0.0005	0.5633	1.4850	AID661600
Cyclin-dependent kinase 2	Homo sapiens (human)	Ki	0.6166	0.0005	0.6427	5.0000	AID661600
Tyrosine-protein kinase ZAP-70	Homo sapiens (human)	Ki	10.0000	2.6303	5.4151	8.2000	AID661601
Protein-tyrosine kinase 2-beta	Homo sapiens (human)	Ki	0.1622	0.0105	0.2800	0.9333	AID661602
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NPYLR7B	Aedes aegypti (yellow fever mosquito)	EC50 (µMol)	20.0000	0.0390	2.2899	18.3000	AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
jumonji domain containing 2C, partial	Homo sapiens (human)	AC50	10.8100	0.4245	6.7462	15.2100	AID488835
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of chronic inflammatory response	Aromatase	Homo sapiens (human)
steroid biosynthetic process	Aromatase	Homo sapiens (human)
estrogen biosynthetic process	Aromatase	Homo sapiens (human)
androgen catabolic process	Aromatase	Homo sapiens (human)
syncytium formation	Aromatase	Homo sapiens (human)
negative regulation of macrophage chemotaxis	Aromatase	Homo sapiens (human)
sterol metabolic process	Aromatase	Homo sapiens (human)
female genitalia development	Aromatase	Homo sapiens (human)
mammary gland development	Aromatase	Homo sapiens (human)
uterus development	Aromatase	Homo sapiens (human)
prostate gland growth	Aromatase	Homo sapiens (human)
testosterone biosynthetic process	Aromatase	Homo sapiens (human)
positive regulation of estradiol secretion	Aromatase	Homo sapiens (human)
female gonad development	Aromatase	Homo sapiens (human)
response to estradiol	Aromatase	Homo sapiens (human)
protein phosphorylation	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	G1/S-specific cyclin-E1	Homo sapiens (human)
telomere maintenance	G1/S-specific cyclin-E1	Homo sapiens (human)
DNA replication initiation	G1/S-specific cyclin-E1	Homo sapiens (human)
homologous chromosome pairing at meiosis	G1/S-specific cyclin-E1	Homo sapiens (human)
Wnt signaling pathway	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of protein localization	G1/S-specific cyclin-E1	Homo sapiens (human)
cell division	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferation	G1/S-specific cyclin-E1	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	G1/S-specific cyclin-E1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA repair	Cyclin-dependent kinase 2	Homo sapiens (human)
chromatin remodeling	Cyclin-dependent kinase 2	Homo sapiens (human)
DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
potassium ion transport	Cyclin-dependent kinase 2	Homo sapiens (human)
centriole replication	Cyclin-dependent kinase 2	Homo sapiens (human)
Ras protein signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Cyclin-dependent kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of heterochromatin formation	Cyclin-dependent kinase 2	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiation	Cyclin-dependent kinase 2	Homo sapiens (human)
telomere maintenance in response to DNA damage	Cyclin-dependent kinase 2	Homo sapiens (human)
post-translational protein modification	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA replication	Cyclin-dependent kinase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome duplication	Cyclin-dependent kinase 2	Homo sapiens (human)
cell division	Cyclin-dependent kinase 2	Homo sapiens (human)
meiotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular response to nitric oxide	Cyclin-dependent kinase 2	Homo sapiens (human)
cellular senescence	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Cyclin-dependent kinase 2	Homo sapiens (human)
signal transduction	Cyclin-dependent kinase 2	Homo sapiens (human)
regulation of gene expression	Cyclin-dependent kinase 2	Homo sapiens (human)
response to organic substance	Cyclin-dependent kinase 2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
positive thymic T cell selection	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
positive regulation of T cell differentiation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
immune response	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
calcium-mediated signaling	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell differentiation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell activation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
B cell activation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
beta selection	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
negative thymic T cell selection	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
positive regulation of alpha-beta T cell differentiation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
positive regulation of alpha-beta T cell proliferation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell aggregation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell migration	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
MAPK cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
oocyte maturation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hypoxia	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
sprouting angiogenesis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
adaptive immune response	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
marginal zone B cell differentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to ischemia	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein phosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular defense response	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
signal transduction	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell surface receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
signal complex assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
integrin-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell population proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of cell population proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of cell shape	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to xenobiotic stimulus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to mechanical stimulus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hormone	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to glucose	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of endothelial cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of muscle cell apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of macrophage chemotaxis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of neuron projection development	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glial cell proliferation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of cell adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell growth	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of bone mineralization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of actin filament polymerization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cortical cytoskeleton organization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neuron projection development	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of actin cytoskeleton organization	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to immobilization stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cocaine	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to hydrogen peroxide	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
activation of Janus kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
stress fiber assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cation stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of potassium ion transport	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of neuron apoptotic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
blood vessel endothelial cell migration	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
bone resorption	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to ethanol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
negative regulation of myeloid cell differentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of translation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of angiogenesis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of protein kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of JNK cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein autophosphorylation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of synaptic plasticity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to cAMP	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
response to calcium ion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
long-term synaptic potentiation	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
long-term synaptic depression	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein-containing complex assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
chemokine-mediated signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular response to retinoic acid	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cellular response to fluid shear stress	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
endothelin receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of postsynaptic density assembly	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of excitatory postsynaptic potential	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of B cell chemotaxis	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
positive regulation of DNA biosynthetic process	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
iron ion binding	Aromatase	Homo sapiens (human)
steroid hydroxylase activity	Aromatase	Homo sapiens (human)
electron transfer activity	Aromatase	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Aromatase	Homo sapiens (human)
oxygen binding	Aromatase	Homo sapiens (human)
heme binding	Aromatase	Homo sapiens (human)
aromatase activity	Aromatase	Homo sapiens (human)
protein binding	G1/S-specific cyclin-E1	Homo sapiens (human)
kinase activity	G1/S-specific cyclin-E1	Homo sapiens (human)
protein kinase binding	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activity	G1/S-specific cyclin-E1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
magnesium ion binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 2	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 2	Homo sapiens (human)
protein domain specific binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 2	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
calmodulin-dependent protein kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein tyrosine kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ATP binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
ubiquitin protein ligase binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glutamate receptor binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
3-phosphoinositide-dependent protein kinase binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
protein-containing complex binding	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neurotransmitter receptor regulator activity	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum	Aromatase	Homo sapiens (human)
endoplasmic reticulum membrane	Aromatase	Homo sapiens (human)
membrane	Aromatase	Homo sapiens (human)
endoplasmic reticulum	Aromatase	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
cytosol	G1/S-specific cyclin-E1	Homo sapiens (human)
cyclin E1-CDK2 complex	G1/S-specific cyclin-E1	Homo sapiens (human)
centrosome	G1/S-specific cyclin-E1	Homo sapiens (human)
nucleus	G1/S-specific cyclin-E1	Homo sapiens (human)
cytoplasm	G1/S-specific cyclin-E1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 2	Homo sapiens (human)
condensed chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
X chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
Y chromosome	Cyclin-dependent kinase 2	Homo sapiens (human)
male germ cell nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
nuclear envelope	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
endosome	Cyclin-dependent kinase 2	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 2	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 2	Homo sapiens (human)
Cajal body	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin A2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E1-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin E2-CDK2 complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 2	Homo sapiens (human)
transcription regulator complex	Cyclin-dependent kinase 2	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 2	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 2	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
immunological synapse	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
cell-cell junction	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
T cell receptor complex	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ZAP-70	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
NMDA selective glutamate receptor complex	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
nucleus	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytoplasm	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytosol	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cytoskeleton	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell cortex	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic density	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
lamellipodium	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
dendrite	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
growth cone	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
neuronal cell body	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
cell body	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
perinuclear region of cytoplasm	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
apical dendrite	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
presynapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
glutamatergic synapse	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
postsynaptic density, intracellular component	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
dendritic spine	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
focal adhesion	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
plasma membrane	Protein-tyrosine kinase 2-beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224754	Delta TM value showing the stabilisation of CAMK2G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224778	Delta TM value showing the stabilisation of NEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224792	Delta TM value showing the stabilisation of RIOK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224758	Delta TM value showing the stabilisation of CDK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224779	Delta TM value showing the stabilisation of NEK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID661600	Inhibition of human recombinant CDK2/CycE using HHASPRK as substrate by ESI-MS analysis	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Identification of binding specificity-determining features in protein families.
AID1224791	Delta TM value showing the stabilisation of PRKACA produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224765	Delta TM value showing the stabilisation of CK1G2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID661602	Inhibition of human recombinant PYK2 by ESI-MS analysis	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Identification of binding specificity-determining features in protein families.
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224786	Delta TM value showing the stabilisation of PIM1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID69576	Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
AID1224789	Delta TM value showing the stabilisation of PLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224790	Delta TM value showing the stabilisation of PLK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224797	Delta TM value showing the stabilisation of MPSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224757	Delta TM value showing the stabilisation of CDK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224760	Delta TM value showing the stabilisation of CHEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224801	Delta TM value showing the stabilisation of MST1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224772	Delta TM value showing the stabilisation of MAP2K6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224755	Delta TM value showing the stabilisation of CAMK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224799	Delta TM value showing the stabilisation of NDR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224770	Delta TM value showing the stabilisation of JAK1~B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID69407	Inhibition of compound Epidermal growth factor receptor autophosphorylation (no data)	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.
AID429611	Inhibition of aromatase	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis and biochemical evaluation of a range of sulfonated derivatives of 4-hydroxybenzyl imidazole as highly potent inhibitors of rat testicular 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)).
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224763	Delta TM value showing the stabilisation of CLK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224773	Delta TM value showing the stabilisation of ASK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224788	Delta TM value showing the stabilisation of PIM3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224793	Delta TM value showing the stabilisation of RSK2a produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224777	Delta TM value showing the stabilisation of MST4(1) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224768	Delta TM value showing the stabilisation of DMPK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224800	Delta TM value showing the stabilisation of MST4 (2) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224759	Delta TM value showing the stabilisation of CDKL1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325789	Inhibition of GTPase activity of transducer	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224802	Delta TM value showing the stabilisation of TNIK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224785	Delta TM value showing the stabilisation of PDK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224766	Delta TM value showing the stabilisation of CK1G3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780	Delta TM value showing the stabilisation of OSR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224805	Delta TM value showing the stabilisation of VRK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID69399	Inhibition of epidermal growth factor receptor (EGFR) phosphorylation of the exogenous substrate poly(Glu6, Ala3,Tyr) (polyGAT)	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.
AID1224803	Delta TM value showing the stabilisation of PBK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224775	Delta TM value showing the stabilisation of ERK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224753	Delta TM value showing the stabilisation of CAMK2D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224804	Delta TM value showing the stabilisation of VRK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224751	Delta TM value showing the stabilisation of CAMK2A produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1224795	Delta TM value showing the stabilisation of SLK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224774	Delta TM value showing the stabilisation of p38beta produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325790	Inhibition of EGFR autophosphorylation	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224764	Delta TM value showing the stabilisation of CK1G1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224748	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224783	Delta TM value showing the stabilisation of PAK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID661601	Inhibition of human recombinant ZAP70 using EEEEYEEEE as substrate by ESI-MS analysis	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Identification of binding specificity-determining features in protein families.
AID1224776	Delta TM value showing the stabilisation of ERK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224784	Delta TM value showing the stabilisation of PCTK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224756	Delta TM value showing the stabilisation of CAMKK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224752	Delta TM value showing the stabilisation of CAMK2B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224798	Delta TM value showing the stabilisation of DRAK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224762	Delta TM value showing the stabilisation of CLK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224761	Delta TM value showing the stabilisation of CLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224750	Delta TM value showing the stabilisation of CAMK1G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224749	Delta TM value showing the stabilisation of CAMK1D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787	Delta TM value showing the stabilisation of PIM2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID326316	Effect on catechol-O-methyltransferase assessed as stimulation of methylation of mouse heart cytosol proteins per miligram of protein at 100 uM after 2 hrs by vapor-diffusion assay	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	S-adenosylmethionine-dependent protein methylation in mammalian cytosol via tyrphostin modification by catechol-O-methyltransferase.
AID1224769	Delta TM value showing the stabilisation of GSK3B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224807	Delta TM value showing the stabilisation of YSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224794	Delta TM value showing the stabilisation of RSK2b produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224782	Delta TM value showing the stabilisation of PAK5 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806	Delta TM value showing the stabilisation of VRK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224771	Delta TM value showing the stabilisation of MEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID326317	Activity of pig recombinant catechol-O-methyltransferase assessed per unit enzyme	2007	The Journal of biological chemistry, Oct-19, Volume: 282, Issue:42	S-adenosylmethionine-dependent protein methylation in mammalian cytosol via tyrphostin modification by catechol-O-methyltransferase.
AID1224781	Delta TM value showing the stabilisation of PAK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID69555	Inhibitory concentration of EGF dependent autophosphorylation of epidermal growth factor receptor kinase	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
AID1224796	Delta TM value showing the stabilisation of LOK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224767	Delta TM value showing the stabilisation of DAPK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1795632	EGFR assay from Article 10.1021/jm00130a020: \\Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.\\	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (1.27)	18.7374
1990's	59 (37.34)	18.2507
2000's	62 (39.24)	29.6817
2010's	27 (17.09)	24.3611
2020's	8 (5.06)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	160 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
4-hydroxybenzoic acid	[no description available]	medium	1	monohydroxybenzoic acid	algal metabolite; plant metabolite
dihydroxyphenylalanine	[no description available]	medium	1	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
ag 127	[no description available]	medium	3	nitrophenol
tyrphostin 25	[no description available]	medium	8	benzenetriol
tyrphostin a1	[no description available]	medium	3	methoxybenzenes	geroprotector
tyrphostin a9	[no description available]	medium	4	alkylbenzene	geroprotector
levodopa	[no description available]	medium	2	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
tyrphostin 8	[no description available]	medium	2	phenols
trans-4-coumaric acid	[no description available]	medium	1	4-coumaric acid	food component; mouse metabolite; plant metabolite
alpha-cyanocinnamate	[no description available]	medium	1
ag-213	[no description available]	medium	13
caffeic acid	[no description available]	medium	2	caffeic acid	geroprotector; mouse metabolite
4-nitrocatechol	[no description available]	medium	1	C-nitro compound; catechols	human xenobiotic metabolite; lipoxygenase inhibitor
erbstatin	[no description available]	medium	4
ag 99	[no description available]	medium	7
ag 127	[no description available]	medium	1
alpha-cyano-4-hydroxycinnamic acid	[no description available]	medium	1	monohydroxycinnamic acid; nitrile; phenols	MALDI matrix material
ag 30	[no description available]	medium	2
ag 112	[no description available]	medium	3
ag 183	[no description available]	medium	6
AG-370	[no description available]	medium	1	indoles
ag 538	[no description available]	medium	2
gamma-aminobutyric acid	[no description available]	medium	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
acetamide	[no description available]	medium	1	acetamides; carboximidic acid; monocarboxylic acid amide; N-acylammonia
quinacrine	[no description available]	medium	1	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
catechol	[no description available]	medium	2	catechols	allelochemical; genotoxin; plant metabolite
taxifolin	[no description available]	medium	2	3'-hydroxyflavanones; 4'-hydroxyflavanones; dihydroflavonols; pentahydroxyflavanone; secondary alpha-hydroxy ketone
phosphonoacetic acid	[no description available]	medium	2	monocarboxylic acid; phosphonic acids	antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
3,4-dihydroxyphenylacetic acid	[no description available]	medium	2	catechols; dihydroxyphenylacetic acid	human metabolite
aminocaproic acid	[no description available]	medium	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
diacetyl	[no description available]	medium	1	alpha-diketone	Escherichia coli metabolite; Saccharomyces cerevisiae metabolite
hydroquinone	[no description available]	medium	2	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
melatonin	[no description available]	medium	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
n-acetylserotonin	[no description available]	medium	1	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist
pyrazinamide	[no description available]	medium	1	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
quinolinic acid	[no description available]	medium	1	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
taurine	[no description available]	medium	2	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate	[no description available]	medium	1	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
alpha-methyl-4-carboxyphenylglycine	[no description available]	medium	1
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	[no description available]	medium	1
1-hydroxy-3-amino-2-pyrrolidone	[no description available]	medium	1
ibotenic acid	[no description available]	medium	1	non-proteinogenic alpha-amino acid	neurotoxin
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane	[no description available]	medium	1
sk&f-38393	[no description available]	medium	2	benzazepine; catechols; secondary amino compound
vanilmandelic acid	[no description available]	medium	1	2-hydroxy monocarboxylic acid; aromatic ether; phenols	human metabolite
1,10-diaminodecane	[no description available]	medium	2
1,3-diethyl-8-phenylxanthine	[no description available]	medium	1
1,3-dipropyl-8-cyclopentylxanthine	[no description available]	medium	2	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1,3-dipropyl-8-(4-sulfophenyl)xanthine	[no description available]	medium	1
1,5-dihydroxyisoquinoline	[no description available]	medium	1	isoquinolinol	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pk 11195	[no description available]	medium	2	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-(2-trifluoromethylphenyl)imidazole	[no description available]	medium	1	imidazoles
1-aminobenzotriazole	[no description available]	medium	2
1-methylimidazole	[no description available]	medium	1	imidazoles
edelfosine	[no description available]	medium	1	glycerophosphocholine
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	[no description available]	medium	2	oxadiazoloquinoxaline	EC 4.6.1.2 (guanylate cyclase) inhibitor
2,2'-dipyridyl	[no description available]	medium	2	bipyridine	chelator; ferroptosis inhibitor
2-hydroxysaclofen	[no description available]	medium	1	organochlorine compound
3,4-dichloroisocoumarin	[no description available]	medium	2	isocoumarins; organochlorine compound	geroprotector; serine protease inhibitor
phaclofen	[no description available]	medium	1	organophosphate oxoanion; zwitterion
3-aminobenzamide	[no description available]	medium	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-bromo-7-nitroindazole	[no description available]	medium	1
enprofylline	[no description available]	medium	1	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
3-nitropropionic acid	[no description available]	medium	1	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
4-amino-1,8-naphthalimide	[no description available]	medium	2	benzoisoquinoline; dicarboximide
4-aminopyridine	[no description available]	medium	1	aminopyridine; aromatic amine	avicide; orphan drug; potassium channel blocker
homovanillic acid	[no description available]	medium	2	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
4-hydroxybenzoic acid hydrazide	[no description available]	medium	1	carbohydrazide; phenols
4-phenyl-3-furoxancarbonitrile	[no description available]	medium	2	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
5,5-dimethyl-1-pyrroline-1-oxide	[no description available]	medium	1	1-pyrroline nitrones	neuroprotective agent; spin trapping reagent
phenytoin	[no description available]	medium	1	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
5,7-dichlorokynurenic acid	[no description available]	medium	1	quinolines
5-(n,n-hexamethylene)amiloride	[no description available]	medium	2	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
ethylisopropylamiloride	[no description available]	medium	2	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker
5-fluoroindole-2-carboxylic acid	[no description available]	medium	2	indolyl carboxylic acid
hydroxyindoleacetic acid	[no description available]	medium	1	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
phenanthridone	[no description available]	medium	2	lactam; phenanthridines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; immunosuppressive agent; mutagen
6-chloromelatonin	[no description available]	medium	1	acetamides
6-hydroxymelatonin	[no description available]	medium	1	acetamides; tryptamines	metabolite; mouse metabolite
6-methoxytryptoline	[no description available]	medium	1
6-nitroso-1,2-benzopyrone	[no description available]	medium	2
7-chlorokynurenic acid	[no description available]	medium	1	organochlorine compound; quinolinemonocarboxylic acid	neuroprotective agent; NMDA receptor antagonist
7-nitroindazole	[no description available]	medium	1
8-(4-sulfophenyl)theophylline	[no description available]	medium	2
8-cyclopentyl-1,3-dimethylxanthine	[no description available]	medium	1	oxopurine
8-phenyltheophylline	[no description available]	medium	1
acetazolamide	[no description available]	medium	1	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide	[no description available]	medium	1	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
rtki cpd	[no description available]	medium	2	aromatic ether; monochlorobenzenes; quinazolines	antineoplastic agent; antiviral agent; epidermal growth factor receptor antagonist; geroprotector
1-aminoindan-1,5-dicarboxylic acid	[no description available]	medium	1
albuterol	[no description available]	medium	1	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alpha-methyltyrosine methyl ester	[no description available]	medium	1
altretamine	[no description available]	medium	1	triamino-1,3,5-triazine
amfonelic acid	[no description available]	medium	1
amifostine anhydrous	[no description available]	medium	1	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
theophylline	[no description available]	medium	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amoxapine	[no description available]	medium	2	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
aniracetam	[no description available]	medium	1	N-acylpyrrolidine; pyrrolidin-2-ones
2-amino-4-phosphonobutyric acid	[no description available]	medium	1
aspirin	[no description available]	medium	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atenolol	[no description available]	medium	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate	[no description available]	medium	1	alpha-amino acid
aurintricarboxylic acid	[no description available]	medium	2	monohydroxybenzoic acid; quinomethanes; tricarboxylic acid	fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist
azathioprine	[no description available]	medium	2	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelaic acid	[no description available]	medium	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite
baclofen	[no description available]	medium	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bay-k-8644	[no description available]	medium	3	(trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester
benzamide	[no description available]	medium	1	benzamides
bepridil	[no description available]	medium	1	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
bml 190	[no description available]	medium	2	N-acylindole
brimonidine	[no description available]	medium	2	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent
bumetanide	[no description available]	medium	2	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
caffeine	[no description available]	medium	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
carbamazepine	[no description available]	medium	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbetapentane	[no description available]	medium	1	benzenes
carisoprodol	[no description available]	medium	1	carbamate ester	muscle relaxant
carmustine	[no description available]	medium	1	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
cgs 12066	[no description available]	medium	1	N-arylpiperazine; organofluorine compound; pyrroloquinoxaline	serotonergic agonist
cgs 15943	[no description available]	medium	2	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
chlorambucil	[no description available]	medium	2	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlormezanone	[no description available]	medium	1	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chlorothiazide	[no description available]	medium	1	benzothiadiazine	antihypertensive agent; diuretic
chlorpropamide	[no description available]	medium	1	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorzoxazone	[no description available]	medium	1	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cilostamide	[no description available]	medium	2	quinolines
cilostazol	[no description available]	medium	2	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine	[no description available]	medium	2	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cinoxacin	[no description available]	medium	2	cinnolines; oxacycle; oxo carboxylic acid	antibacterial drug; antiinfective agent
ciprofibrate	[no description available]	medium	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
clofibrate	[no description available]	medium	1	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clotrimazole	[no description available]	medium	2	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cx546	[no description available]	medium	1
cyclothiazide	[no description available]	medium	1	benzothiadiazine	antihypertensive agent; diuretic
dephostatin	[no description available]	medium	2
nonivamide	[no description available]	medium	1	capsaicinoid; phenols	lachrymator
r 59022	[no description available]	medium	2	diarylmethane
diazoxide	[no description available]	medium	1	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
pentetic acid	[no description available]	medium	1	pentacarboxylic acid	copper chelator
diphenyleneiodonium	[no description available]	medium	1	organic cation
dipyridamole	[no description available]	medium	2	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide	[no description available]	medium	1	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram	[no description available]	medium	2	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
2-amino-7-phosphonoheptanoic acid	[no description available]	medium	1
thiorphan	[no description available]	medium	1	N-acyl-amino acid
2,3-dimethoxy-1,4-naphthoquinone	[no description available]	medium	2	1,4-naphthoquinones
domperidone	[no description available]	medium	2	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
droperidol	[no description available]	medium	2	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
ebselen	[no description available]	medium	2	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
ellipticine	[no description available]	medium	3	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
emodin	[no description available]	medium	2	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
ethosuximide	[no description available]	medium	1	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
etodolac	[no description available]	medium	1	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
felbamate	[no description available]	medium	1	carbamate ester	anticonvulsant; neuroprotective agent
felodipine	[no description available]	medium	2	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate	[no description available]	medium	2	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
flumazenil	[no description available]	medium	1	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorouracil	[no description available]	medium	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluspirilene	[no description available]	medium	2	diarylmethane
flutamide	[no description available]	medium	2	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
formoterol fumarate	[no description available]	medium	2	formamides; phenols; phenylethanolamines; secondary alcohol; secondary amino compound
fpl 64176	[no description available]	medium	2	carboxylic ester; pyrroles	calcium channel agonist
furafylline	[no description available]	medium	1	oxopurine
furosemide	[no description available]	medium	2	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
fusaric acid	[no description available]	medium	1	aromatic carboxylic acid; pyridines
gabapentin	[no description available]	medium	1	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
4-amino-5-hexynoic acid	[no description available]	medium	1
glipizide	[no description available]	medium	1	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide	[no description available]	medium	2	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
1-(5-isoquinolinesulfonyl)piperazine	[no description available]	medium	1	isoquinolines
haloperidol	[no description available]	medium	2	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hemicholinium 3	[no description available]	medium	1	morpholines
4-fluorohexahydrosiladifenidol	[no description available]	medium	1
hydrochlorothiazide	[no description available]	medium	1	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxyurea	[no description available]	medium	1	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
ibudilast	[no description available]	medium	1	pyrazolopyridine
ibuprofen	[no description available]	medium	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
ic 261	[no description available]	medium	2	indoles
ifenprodil	[no description available]	medium	1	piperidines
indirubin-3'-monoxime	[no description available]	medium	3
indomethacin	[no description available]	medium	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoacetamide	[no description available]	medium	1
1-methyl-3-isobutylxanthine	[no description available]	medium	5	3-isobutyl-1-methylxanthine
4-piperidinecarboxylic acid	[no description available]	medium	2
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline	[no description available]	medium	1
jl 18	[no description available]	medium	2
nsc 664704	[no description available]	medium	3	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketoconazole	[no description available]	medium	3	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen	[no description available]	medium	1	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
kynurenic acid	[no description available]	medium	1	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid	[no description available]	medium	1	alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids	human metabolite; metabotropic glutamate receptor antagonist
lamotrigine	[no description available]	medium	1	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole	[no description available]	medium	2	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
beta-lapachone	[no description available]	medium	2	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
leflunomide	[no description available]	medium	1	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
linopirdine	[no description available]	medium	2	indoles
loratadine	[no description available]	medium	2	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
loxoprofen	[no description available]	medium	1	cyclopentanones; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one	[no description available]	medium	5	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
meclofenamate sodium anhydrous	[no description available]	medium	1	organic sodium salt
methiothepin	[no description available]	medium	1	aryl sulfide; dibenzothiepine; N-alkylpiperazine; tertiary amino compound	antipsychotic agent; dopaminergic antagonist; geroprotector; serotonergic antagonist
methoctramine	[no description available]	medium	1	aromatic ether; tetramine	muscarinic antagonist
nocodazole	[no description available]	medium	2	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
3-Hydroxy-alpha-methyl-DL-tyrosine	[no description available]	medium	1	benzenes; monocarboxylic acid
metolazone	[no description available]	medium	2	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
milrinone	[no description available]	medium	1	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil	[no description available]	medium	1	dialkylarylamine; tertiary amino compound
mitotane	[no description available]	medium	1	diarylmethane
mitoxantrone	[no description available]	medium	2	dihydroxyanthraquinone	analgesic; antineoplastic agent
ml 7	[no description available]	medium	2	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide	[no description available]	medium	1	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
n-bromoacetamide	[no description available]	medium	1
ethylmaleimide	[no description available]	medium	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
fg 7142	[no description available]	medium	2	beta-carbolines
fenamic acid	[no description available]	medium	1	aminobenzoic acid; secondary amino compound	membrane transport modulator
n 0840	[no description available]	medium	2
nialamide	[no description available]	medium	2	organonitrogen compound; organooxygen compound
niclosamide	[no description available]	medium	2	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
nifedipine	[no description available]	medium	3	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
niflumic acid	[no description available]	medium	1	aromatic carboxylic acid; pyridines
nilutamide	[no description available]	medium	1	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide	[no description available]	medium	1	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine	[no description available]	medium	2	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nipecotic acid	[no description available]	medium	1	beta-amino acid; piperidinemonocarboxylic acid
nitrendipine	[no description available]	medium	2	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
masoprocol	[no description available]	medium	2	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
5-nitro-2-(3-phenylpropylamino)benzoic acid	[no description available]	medium	4	nitrobenzoic acid
ns 2028	[no description available]	medium	1
ns 1619	[no description available]	medium	3	(trifluoromethyl)benzenes; benzimidazoles; phenols	potassium channel opener
o(6)-benzylguanine	[no description available]	medium	1
ofloxacin	[no description available]	medium	2	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine	[no description available]	medium	3	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxaprozin	[no description available]	medium	2	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxatomide	[no description available]	medium	2	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
oxiracetam	[no description available]	medium	1	organonitrogen compound; organooxygen compound
oxolinic acid	[no description available]	medium	1	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor
quinone	[no description available]	medium	1	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
fenclonine	[no description available]	medium	1	phenylalanine derivative
palmidrol	[no description available]	medium	2	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
1,7-dimethylxanthine	[no description available]	medium	1	dimethylxanthine	central nervous system stimulant; human blood serum metabolite; human xenobiotic metabolite; mouse metabolite
pd 98059	[no description available]	medium	12	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pentamidine	[no description available]	medium	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentoxifylline	[no description available]	medium	1	oxopurine
perphenazine	[no description available]	medium	2	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenyl biguanide	[no description available]	medium	2	guanidines	central nervous system drug
phenylbutazone	[no description available]	medium	2	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
phloretin	[no description available]	medium	2	dihydrochalcones	antineoplastic agent; plant metabolite
picotamide	[no description available]	medium	2	benzamides
pinacidil	[no description available]	medium	2	pyridines
pindolol	[no description available]	medium	1	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
piperidine-4-sulfonic acid	[no description available]	medium	1
piracetam	[no description available]	medium	1	organonitrogen compound; organooxygen compound
pirenperone	[no description available]	medium	2	aromatic ketone
praziquantel	[no description available]	medium	2	isoquinolines
primidone	[no description available]	medium	1	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
proglumide	[no description available]	medium	1	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite
propentofylline	[no description available]	medium	2	oxopurine
propofol	[no description available]	medium	1	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
pf 5901	[no description available]	medium	2	quinolines
riluzole	[no description available]	medium	2	benzothiazoles
risperidone	[no description available]	medium	2	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
ritanserin	[no description available]	medium	2	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone	[no description available]	medium	1	methoxybenzenes
rolipram	[no description available]	medium	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
salmeterol xinafoate	[no description available]	medium	1	ether; phenols; primary alcohol; secondary alcohol; secondary amino compound
sb 202190	[no description available]	medium	5	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sobuzoxane	[no description available]	medium	1	organic molecular entity
spiroxatrine	[no description available]	medium	2	imidazolidines
sq 22536	[no description available]	medium	1	nucleoside analogue; oxolanes	EC 4.6.1.1 (adenylate cyclase) inhibitor
sulfaphenazole	[no description available]	medium	1	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulpiride	[no description available]	medium	1	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
t0156	[no description available]	medium	2	naphthyridine derivative
1,4-bis(2-(3,5-dichloropyridyloxy))benzene	[no description available]	medium	1
terfenadine	[no description available]	medium	2	diarylmethane
tetraisopropylpyrophosphamide	[no description available]	medium	2	phosphoramide
thalidomide	[no description available]	medium	1	phthalimides; piperidones
theobromine	[no description available]	medium	1	dimethylxanthine	adenosine receptor antagonist; bronchodilator agent; food component; human blood serum metabolite; mouse metabolite; plant metabolite; vasodilator agent
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate	[no description available]	medium	3	trihydroxybenzoic acid
tolazamide	[no description available]	medium	1	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide	[no description available]	medium	1	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid	[no description available]	medium	1
ici 136,753	[no description available]	medium	2	pyrazolopyridine
triamterene	[no description available]	medium	2	pteridines	diuretic; sodium channel blocker
trimethoprim	[no description available]	medium	2	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
tropicamide	[no description available]	medium	1	acetamides
vigabatrin	[no description available]	medium	1	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine	[no description available]	medium	2
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	[no description available]	medium	2	aromatic primary alcohol; furans; indazoles	antineoplastic agent; apoptosis inducer; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
zardaverine	[no description available]	medium	1	organofluorine compound; pyridazinone	anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug
cortisone acetate	[no description available]	medium	1	corticosteroid hormone
corticosterone	[no description available]	medium	3	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
reserpine	[no description available]	medium	2	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
procaine hydrochloride	[no description available]	medium	1	organic molecular entity
isoproterenol hydrochloride	[no description available]	medium	2	catechols
histamine dihydrochloride	[no description available]	medium	1
carbachol	[no description available]	medium	3	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
spironolactone	[no description available]	medium	2	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
estrone	[no description available]	medium	2	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
androsterone	[no description available]	medium	2	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid	androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone
promazine hydrochloride	[no description available]	medium	2	hydrochloride
pilocarpine hydrochloride	[no description available]	medium	1	hydrochloride
dimethylphenylpiperazinium iodide	[no description available]	medium	2	N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt	nicotinic acetylcholine receptor agonist
pentylenetetrazole	[no description available]	medium	1	organic heterobicyclic compound; organonitrogen heterocyclic compound
racepinephrine hydrochloride	[no description available]	medium	2
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride	[no description available]	medium	2
hexamethonium bromide	[no description available]	medium	1
cystamine dihydrochloride	[no description available]	medium	1
cantharidin	[no description available]	medium	2	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
tetraethylammonium chloride	[no description available]	medium	2	organic chloride salt; quaternary ammonium salt	potassium channel blocker
aspartic acid	[no description available]	medium	3	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine	[no description available]	medium	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
vincristine	[no description available]	medium	1	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine	[no description available]	medium	2	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
apomorphine	[no description available]	medium	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
promethazine hydrochloride	[no description available]	medium	2	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative
bromodeoxyuridine	[no description available]	medium	2	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
methoxamine hydrochloride	[no description available]	medium	2	dimethoxybenzene
papaverine hydrochloride	[no description available]	medium	2
bretylium tosylate	[no description available]	medium	2	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
berlition	[no description available]	medium	1	dithiolanes; heterocyclic fatty acid; lipoic acid; thia fatty acid	cofactor; nutraceutical; prosthetic group
methacholine chloride	[no description available]	medium	1	quaternary ammonium salt
androstenedione	[no description available]	medium	3	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
colchicine	[no description available]	medium	2	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
yohimbine hydrochloride	[no description available]	medium	2
gallamine triethiodide	[no description available]	medium	1
cycloheximide	[no description available]	medium	2	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
egtazic acid	[no description available]	medium	2	diether; tertiary amino compound; tetracarboxylic acid	chelator
cycloserine	[no description available]	medium	1	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
17-alpha-hydroxyprogesterone	[no description available]	medium	2	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin
quinacrine monohydrochloride	[no description available]	medium	2
chlorpromazine hydrochloride	[no description available]	medium	2	hydrochloride; phenothiazines	anticoronaviral agent; phenothiazine antipsychotic drug
cytarabine hydrochloride	[no description available]	medium	1
tryptophan	[no description available]	medium	2	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
lidocaine hydrochloride	[no description available]	medium	2	hydrochloride	anti-arrhythmia drug; local anaesthetic
arginine	[no description available]	medium	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
rotenone	[no description available]	medium	2	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
synephrine	[no description available]	medium	1	ethanolamines; phenethylamine alkaloid; phenols	alpha-adrenergic agonist; plant metabolite
pyridostigmine bromide	[no description available]	medium	1	pyridinium salt
imipramine hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant
neostigmine bromide	[no description available]	medium	1	bromide salt
edrophonium chloride	[no description available]	medium	1	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
suramin sodium	[no description available]	medium	2	organic sodium salt	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
pyrazolanthrone	[no description available]	medium	3	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
methapyrilene hydrochloride	[no description available]	medium	2	hydrochloride	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
tetrracaine hydrochloride	[no description available]	medium	1	benzoate ester
chelidamic acid	[no description available]	medium	1
2-chloroadenosine	[no description available]	medium	2	purine nucleoside
diphenhydramine hydrochloride	[no description available]	medium	2	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
cysteamine hydrochloride	[no description available]	medium	1
propantheline bromide	[no description available]	medium	2	xanthenes
hydralazine hydrochloride	[no description available]	medium	1	hydrochloride	antihypertensive agent; vasodilator agent
ethamivan	[no description available]	medium	1	methoxybenzenes; phenols
pargyline hydrochloride	[no description available]	medium	2
aminophylline	[no description available]	medium	1	mixture	bronchodilator agent; cardiotonic drug
azacitidine	[no description available]	medium	1	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
orphenadrine hydrochloride	[no description available]	medium	2	hydrochloride	antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
betamethasone	[no description available]	medium	2	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide	[no description available]	medium	2
cyproterone acetate	[no description available]	medium	2	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
bicuculline	[no description available]	medium	1	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
kainic acid	[no description available]	medium	1	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
podophyllotoxin	[no description available]	medium	2	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
tetrahydrozoline hydrochloride	[no description available]	medium	2	hydrochloride	nasal decongestant; sympathomimetic agent; vasoconstrictor agent
dequalinium chloride	[no description available]	medium	2	organic chloride salt	antifungal agent; antineoplastic agent; antiseptic drug; mitochondrial NADH:ubiquinone reductase inhibitor
decamethonium dibromide	[no description available]	medium	2
amitriptyline hydrochloride	[no description available]	medium	2	organic tricyclic compound
naphazoline hydrochloride	[no description available]	medium	2	organic molecular entity
doxylamine succinate	[no description available]	medium	2	organic molecular entity
carbamylhydrazine monohydrochloride	[no description available]	medium	1	organic molecular entity
formestane	[no description available]	medium	2	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
debrisoquin sulfate	[no description available]	medium	1	organic sulfate salt
betaine hydrochloride	[no description available]	medium	1
bethanechol chloride	[no description available]	medium	1	carbamate ester; chloride salt; quaternary ammonium salt	muscarinic agonist
acetylcysteine	[no description available]	medium	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
Mecamylamine hydrochloride	[no description available]	medium	2	monoterpenoid
vinblastine	[no description available]	medium	1
cyproheptadine hydrochloride (anhydrous)	[no description available]	medium	2	hydrochloride
5 alpha-androstane-3 alpha,17 beta-diol	[no description available]	medium	1	androstane-3alpha,17beta-diol	Daphnia magna metabolite; human metabolite
pimozide	[no description available]	medium	2	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
azetidyl-2-carboxylic acid	[no description available]	medium	1	azetidine-2-carboxylic acid
muscarine	[no description available]	medium	1
antazoline hydrochloride	[no description available]	medium	2
doxifluridine	[no description available]	medium	1	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
meclofenoxate hydrochloride	[no description available]	medium	1
clonidine hydrochloride	[no description available]	medium	1	dichlorobenzene
beclomethasone	[no description available]	medium	2	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
buthionine sulfoximine	[no description available]	medium	2	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
mexiletine hydrochloride	[no description available]	medium	2	hydrochloride	anti-arrhythmia drug
cyclophosphamide	[no description available]	medium	1	hydrate	alkylating agent; antineoplastic agent; carcinogenic agent; immunosuppressive agent
suxamethonium chloride	[no description available]	medium	1	chloride salt	muscle relaxant
cyclobenzaprine hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant; muscle relaxant
n-methylaspartate	[no description available]	medium	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
3-deazaadenosine	[no description available]	medium	2
metoclopramide hydrochloride	[no description available]	medium	2
isoetharine mesylate	[no description available]	medium	2
zalcitabine	[no description available]	medium	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
propionylpromazine hydrochloride	[no description available]	medium	2
camptothecin	[no description available]	medium	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
nsc-145,668	[no description available]	medium	1	hydrochloride	antimetabolite; antineoplastic agent
clodronic acid	[no description available]	medium	1	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
benserazide hydrochloride	[no description available]	medium	2	hydrochloride	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
pancuronium bromide	[no description available]	medium	2	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
tetradecanoylphorbol acetate	[no description available]	medium	13	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
danazol	[no description available]	medium	2	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
metergoline	[no description available]	medium	2	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
lisuride	[no description available]	medium	1	monocarboxylic acid amide	antidyskinesia agent; antiparkinson drug; dopamine agonist; serotonergic agonist
disopyramide phosphate	[no description available]	medium	2	organoammonium phosphate
bromocriptine	[no description available]	medium	1	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
ergocristine	[no description available]	medium	1	ergot alkaloid
triamcinolone	[no description available]	medium	1	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
zidovudine	[no description available]	medium	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel	[no description available]	medium	2	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
buspirone hydrochloride	[no description available]	medium	2	hydrochloride	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
etoposide	[no description available]	medium	2	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
propafenone hydrochloride	[no description available]	medium	2	hydrochloride	anti-arrhythmia drug
etazolate hydrochloride	[no description available]	medium	2
butaclamol	[no description available]	medium	1	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
ribavirin	[no description available]	medium	2	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
carbidopa	[no description available]	medium	2	catechols; hydrate; hydrazines; monocarboxylic acid	antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine	[no description available]	medium	1	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
methyldopa	[no description available]	medium	1	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
lonidamine	[no description available]	medium	1	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
dexibuprofen	[no description available]	medium	1	ibuprofen	non-narcotic analgesic; non-steroidal anti-inflammatory drug
quisqualic acid	[no description available]	medium	1	non-proteinogenic alpha-amino acid
pirfenidone	[no description available]	medium	1	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flecainide acetate	[no description available]	medium	2	acetate salt	anti-arrhythmia drug
nicardipine hydrochloride	[no description available]	medium	2	dihydropyridine	geroprotector
idarubicin	[no description available]	medium	2	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
captopril	[no description available]	medium	1	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
terazosin hydrochloride anhydrous	[no description available]	medium	2
pergolide mesylate	[no description available]	medium	2	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
ranitidine hydrochloride	[no description available]	medium	1
colforsin	[no description available]	medium	9	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
cefaclor anhydrous	[no description available]	medium	1	cephalosporin	antibacterial drug; drug allergen
alo 2145	[no description available]	medium	1	hydrochloride	alpha-adrenergic agonist; antiglaucoma drug
enoximone	[no description available]	medium	1	aromatic ketone
atomoxetine	[no description available]	medium	2	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
raloxifene hydrochloride	[no description available]	medium	2	hydrochloride	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
mifepristone	[no description available]	medium	2	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
quinpirole hydrochloride	[no description available]	medium	1
imazodan	[no description available]	medium	1
mibefradil dihydrochloride	[no description available]	medium	2
aptiganel hydrochloride	[no description available]	medium	2
adenosine	[no description available]	medium	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
phenelzine sulfate	[no description available]	medium	2	organic molecular entity
fluoxetine hydrochloride	[no description available]	medium	2	hydrochloride; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
propranolol hydrochloride	[no description available]	medium	2	hydrochloride
bupropion hydrochloride	[no description available]	medium	2	aromatic ketone
diltiazem hydrochloride	[no description available]	medium	1	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent
trazodone hydrochloride	[no description available]	medium	2	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
verapamil hydrochloride	[no description available]	medium	2
doxazosin mesylate	[no description available]	medium	2	methanesulfonate salt	geroprotector
amantadine hydrochloride	[no description available]	medium	2	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist
mevastatin	[no description available]	medium	1	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
chloroquine diphosphate	[no description available]	medium	2
dobutamine hydrochloride	[no description available]	medium	2	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
desipramine hydrochloride	[no description available]	medium	2	hydrochloride	drug allergen
dopamine hydrochloride	[no description available]	medium	2	catecholamine
proadifen hydrochloride	[no description available]	medium	2
4-nitrobenzylthioinosine	[no description available]	medium	2	purine nucleoside
metrifudil	[no description available]	medium	1
rutecarpine	[no description available]	medium	2	beta-carbolines
trihexyphenidyl hydrochloride	[no description available]	medium	2	aralkylamine
thioridazine hydrochloride	[no description available]	medium	2	hydrochloride	first generation antipsychotic; geroprotector
procainamide hydrochloride	[no description available]	medium	1	hydrochloride	anti-arrhythmia drug
siquil	[no description available]	medium	2	hydrochloride	anticoronaviral agent
sotalol hydrochloride	[no description available]	medium	1	hydrochloride	anti-arrhythmia drug; beta-adrenergic antagonist
oxymetazoline hydrochloride	[no description available]	medium	2	hydrochloride	alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent
alprenolol hydrochloride	[no description available]	medium	2	hydrochloride
2-methoxyestradiol	[no description available]	medium	2	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
fluphenazine hydrochloride	[no description available]	medium	2	phenothiazines	anticoronaviral agent
tryptamine monohydrochloride	[no description available]	medium	2
clomipramine hydrochloride	[no description available]	medium	2	hydrochloride	anticoronaviral agent; antidepressant; serotonergic antagonist; serotonergic drug
amiloride hydrochloride	[no description available]	medium	2	hydrate	diuretic; sodium channel blocker
prazosin hydrochloride	[no description available]	medium	2	hydrochloride
mianserin hydrochloride	[no description available]	medium	2	hydrochloride	geroprotector
lomefloxacin hydrochloride	[no description available]	medium	2	hydrochloride	antimicrobial agent; antitubercular agent; photosensitizing agent
fenspiride hydrochloride	[no description available]	medium	2
nilverm	[no description available]	medium	2	organic molecular entity
sanguinarine chloride	[no description available]	medium	2
ropinirole hydrochloride	[no description available]	medium	2	indoles
plasmenylserine	[no description available]	medium	1	O-phosphoserine	EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor; EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
5-aminovaleric acid hydrochloride	[no description available]	medium	1
n-acetyltryptamine	[no description available]	medium	1	acetamides; indoles
D-serine	[no description available]	medium	1	D-alpha-amino acid; serine zwitterion; serine	Escherichia coli metabolite; human metabolite; NMDA receptor agonist
dihydroergotamine mesylate	[no description available]	medium	2	methanesulfonate salt	non-narcotic analgesic; serotonergic agonist; vasoconstrictor agent
ranolazine hydrochloride	[no description available]	medium	2
loxapine succinate	[no description available]	medium	2	succinate salt	geroprotector
guanfacine hydrochloride	[no description available]	medium	2	acetamides	geroprotector
pirenzepine dihydrochloride	[no description available]	medium	1	hydrochloride
labetalol hydrochloride	[no description available]	medium	2	salicylamides
acecainide hydrochloride	[no description available]	medium	1
loperamide hydrochloride	[no description available]	medium	2	hydrochloride	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
maprotiline hydrochloride	[no description available]	medium	2	anthracenes
protoporphyrin ix, disodium salt	[no description available]	medium	1
siguazodan	[no description available]	medium	1	pyridazinone
3-octadecanamido-2-ethoxypropylphosphocholine	[no description available]	medium	1
chelerythrine chloride	[no description available]	medium	3
tosyllysine chloromethyl ketone	[no description available]	medium	2
5-(n-methyl-n-isobutyl)amiloride	[no description available]	medium	2
1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride	[no description available]	medium	2	hydrochloride	EC 2.7.11.13 (protein kinase C) inhibitor
amperozide hydrochloride	[no description available]	medium	2	hydrochloride	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist
pyrrolidine dithiocarbamic acid	[no description available]	medium	2
agroclavine	[no description available]	medium	1	ergot alkaloid
s-methylisothiourea sulfate	[no description available]	medium	1
p-Aminobenzamidine dihydrochloride	[no description available]	medium	2	organic molecular entity
benzamidine hydrochloride	[no description available]	medium	1
ketorolac tromethamine	[no description available]	medium	1	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
methionine sulfoximine	[no description available]	medium	1	L-alpha-amino acid zwitterion; L-methionine derivative; methionine sulfoximine; non-proteinogenic L-alpha-amino acid	EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor; geroprotector
tretazicar	[no description available]	medium	1
carbetapentane citrate	[no description available]	medium	2	carbonyl compound
phentolamine mesylate	[no description available]	medium	2
mephentermine	[no description available]	medium	2	2-aminooctadecane-1,3-diol	EC 2.7.11.13 (protein kinase C) inhibitor; human metabolite; mouse metabolite
oxybutynin hydrochloride	[no description available]	medium	2	hydrochloride
nimustine	[no description available]	medium	1	hydrochloride	antineoplastic agent
cordium	[no description available]	medium	1	hydrate; hydrochloride
L-2-aminoadipic acid	[no description available]	medium	1	2-aminoadipic acid	Escherichia coli metabolite; human metabolite
prilocaine hydrochloride	[no description available]	medium	2	hydrochloride	local anaesthetic
mor-14	[no description available]	medium	1	hydroxypiperidine; piperidine alkaloid; tertiary amino compound	anti-HIV agent; cardioprotective agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite
brexanolone	[no description available]	medium	2	3-hydroxy-5alpha-pregnan-20-one	antidepressant; GABA modulator; human metabolite; intravenous anaesthetic; sedative
phenylisopropyladenosine	[no description available]	medium	1	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
hexamethonium chloride	[no description available]	medium	1
6-(4-nitrobenzylthio)guanosine	[no description available]	medium	2
3-aminopropylphosphonic acid	[no description available]	medium	1	phosphonic acids; primary amino compound; zwitterion	GABAB receptor agonist
5'-n-methylcarboxamideadenosine	[no description available]	medium	1
3,7-dimethyl-1-propargylxanthine	[no description available]	medium	1
zpck	[no description available]	medium	2
n(6)-phenyladenosine	[no description available]	medium	1	purine nucleoside
tetrahydrodeoxycorticosterone	[no description available]	medium	2	21-hydroxy steroid
n-methyladenosine	[no description available]	medium	1	methyladenosine
mizoribine	[no description available]	medium	1	imidazoles	anticoronaviral agent
1-amino-1,3-dicarboxycyclopentane	[no description available]	medium	1
u 73122	[no description available]	medium	6	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
alphaxalone	[no description available]	medium	1	corticosteroid hormone
s-nitrosoglutathione	[no description available]	medium	1	glutathione derivative; nitrosothio compound	bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule
cp-55,940	[no description available]	medium	2
vanoxerine	[no description available]	medium	2	hydrochloride	dopamine uptake inhibitor
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate	[no description available]	medium	2	beta-carbolines
u 69593	[no description available]	medium	2	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
cv 3988	[no description available]	medium	2
beta-carboline-3-carboxylic acid methyl ester	[no description available]	medium	2	beta-carbolines
methoctramine	[no description available]	medium	2	hydrochloride	muscarinic antagonist
hypotaurine	[no description available]	medium	1	aminosulfinic acid; zwitterion	human metabolite; metabolite; mouse metabolite
dihydrokainate	[no description available]	medium	1	dicarboxylic acid
gabazine	[no description available]	medium	1
cl 218872	[no description available]	medium	1	pyridazines; ring assembly
betaxolol hydrochloride	[no description available]	medium	2	hydrochloride	antihypertensive agent; beta-adrenergic antagonist
catechin	[no description available]	medium	1	hydrate	geroprotector
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine	[no description available]	medium	2	hydrobromide	serotonergic antagonist
s-methylthiocitrulline	[no description available]	medium	1	imidothiocarbamic ester; L-arginine derivative; L-ornithine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; neuroprotective agent
dihydrocapsaicin	[no description available]	medium	1	capsaicinoid
ml 9	[no description available]	medium	1
parthenolide	[no description available]	medium	2	germacranolide
3',4'-dichlorobenzamil	[no description available]	medium	2	guanidines; pyrazines
1-(carboxymethylthio)tetradecane	[no description available]	medium	1	straight-chain fatty acid
2-iodomelatonin	[no description available]	medium	1	acetamides
arcaine, sulfate	[no description available]	medium	1
gr 113808	[no description available]	medium	2	indolyl carboxylate ester; piperidines; sulfonamide	serotonergic antagonist
gallopamil hydrochloride	[no description available]	medium	2
gamma-glutamylaminomethylsulfonic acid	[no description available]	medium	1
buthionine sulfoximine	[no description available]	medium	2	2-amino-4-(S-butylsulfonimidoyl)butanoic acid	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
sb 204070a	[no description available]	medium	2
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine	[no description available]	medium	2	(trifluoromethyl)benzenes; N-alkylpiperazine; N-arylpiperazine; primary arylamine; substituted aniline	geroprotector; serotonergic agonist
l 655240	[no description available]	medium	1	methylindole
san 58035	[no description available]	medium	2
nnc 711	[no description available]	medium	1
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide	[no description available]	medium	2	diarylmethane
e 64	[no description available]	medium	2	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
azetidine-2,4-dicarboxylic acid	[no description available]	medium	1
pre 084	[no description available]	medium	2	morpholines
methotrexate	[no description available]	medium	2	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol	[no description available]	medium	2
sr 2640	[no description available]	medium	2	quinolines
ici 204448	[no description available]	medium	1
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride	[no description available]	medium	1
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide	[no description available]	medium	2	phenylindole
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan	[no description available]	medium	1
8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine	[no description available]	medium	2
l 741626	[no description available]	medium	2	piperidines
nisoxetine hydrochloride	[no description available]	medium	2
ng-nitroarginine methyl ester	[no description available]	medium	1	hydrochloride	EC 1.14.13.39 (nitric oxide synthase) inhibitor
tilarginine acetate	[no description available]	medium	1
alpha-guanidinoglutaric acid	[no description available]	medium	1	L-glutamic acid derivative
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer	[no description available]	medium	2
imidazole-4-acetic acid hydrochloride	[no description available]	medium	1
nsc-141549	[no description available]	medium	2
2-chloro-2-deoxyglucose	[no description available]	medium	1
idazoxan hydrochloride	[no description available]	medium	2
isoguvacine hydrochloride	[no description available]	medium	1
8-methoxymethyl-3-isobutyl-1-methylxanthine	[no description available]	medium	1	oxopurine
cyc 202	[no description available]	medium	3	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
Serotonin hydrochloride	[no description available]	medium	1	tryptamines
n-phthaloylglutamic acid	[no description available]	medium	1	L-glutamic acid derivative; phthalimides
1,3-dipropyl-7-methylxanthine	[no description available]	medium	1
ag 3-5	[no description available]	medium	1	C-nitro compound
n-n-propylnorapomorphine	[no description available]	medium	1	aporphine alkaloid
urapidil monohydrochloride	[no description available]	medium	2
aminopterin	[no description available]	medium	2	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
azepexole, dihydrochloride	[no description available]	medium	1
2,5-dimethoxy-4-iodoamphetamine hydrochloride	[no description available]	medium	1
abt 980	[no description available]	medium	2
sk&f 75670	[no description available]	medium	2
esatenolol	[no description available]	medium	1	atenolol	beta-adrenergic antagonist
nbi 27914	[no description available]	medium	2	dialkylarylamine; tertiary amino compound
sb 216763	[no description available]	medium	2	indoles; maleimides
(R)-atenolol	[no description available]	medium	1	atenolol
memantine hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
pefabloc	[no description available]	medium	1
pongidae	[no description available]	medium	2
succinylproline	[no description available]	medium	1	N-acyl-amino acid
sb 205384	[no description available]	medium	2	thienopyridine
hydrastine	[no description available]	medium	2	isoquinolines	metabolite
gabaculine hydrochloride	[no description available]	medium	1
etiron monohydrobromide	[no description available]	medium	1
bmy 7378	[no description available]	medium	1
vesamicol	[no description available]	medium	1
cortisone	[no description available]	medium	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
vincristine sulfate	[no description available]	medium	2	organic sulfate salt	antineoplastic agent; geroprotector
n-methylserotonin oxalate salt	[no description available]	medium	1
nsc 95397	[no description available]	medium	2	1,4-naphthoquinones
wortmannin	[no description available]	medium	16	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
lithium chloride	[no description available]	medium	1	inorganic chloride; lithium salt	antimanic drug; geroprotector
canavanine	[no description available]	medium	1	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	phytogenic insecticide; plant metabolite
5-hydroxytryptophan	[no description available]	medium	1	5-hydroxytryptophan; amino acid zwitterion; hydroxy-L-tryptophan; non-proteinogenic L-alpha-amino acid	human metabolite; mouse metabolite; plant metabolite
ouabain	[no description available]	medium	4	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
tosylphenylalanyl chloromethyl ketone	[no description available]	medium	1	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
monoiodotyrosine	[no description available]	medium	1	amino acid zwitterion; L-tyrosine derivative; monoiodotyrosine; non-proteinogenic L-alpha-amino acid	EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor; human metabolite; mouse metabolite
nitroarginine	[no description available]	medium	1	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid
willardiine	[no description available]	medium	1	amino acid zwitterion; L-alanine derivative; non-proteinogenic L-alpha-amino acid
cortodoxone	[no description available]	medium	2	deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
amiodarone hydrochloride	[no description available]	medium	2	aromatic ketone
dicyclomine hydrochloride	[no description available]	medium	2	hydrochloride	antispasmodic drug; muscarinic antagonist
metyrosine	[no description available]	medium	1	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
nortriptyline hydrochloride	[no description available]	medium	2	organic tricyclic compound	geroprotector
paromomycin sulfate	[no description available]	medium	1
Dubinidine	[no description available]	medium	1	organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle
cyclopamine	[no description available]	medium	1	piperidines	glioma-associated oncogene inhibitor
s-(4-azidophenacyl)glutathione	[no description available]	medium	1	peptide
hydroxylamine hydrochloride	[no description available]	medium	2	organic molecular entity
sb 228357	[no description available]	medium	2	indolyl carboxylic acid
3,5-dihydroxyphenylglycine	[no description available]	medium	1	amino acid zwitterion; non-proteinogenic L-alpha-amino acid; resorcinols
actinonin	[no description available]	medium	2
vinpocetine	[no description available]	medium	2	alkaloid	geroprotector
dihydroergocristine monomesylate	[no description available]	medium	2	methanesulfonate salt	alpha-adrenergic antagonist; geroprotector; vasodilator agent
tretinoin	[no description available]	medium	2	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
resveratrol	[no description available]	medium	2	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
oleic acid	[no description available]	medium	1	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
thapsigargin	[no description available]	medium	3	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
brivudine	[no description available]	medium	1
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol	[no description available]	medium	2	carbotetracyclic compound; polyphenol	estrogen receptor agonist; estrogen receptor antagonist; geroprotector; neuroprotective agent
2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid	[no description available]	medium	1
adenosine-5'-(n-ethylcarboxamide)	[no description available]	medium	1	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
L-cycloserine	[no description available]	medium	1	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
1,4-dideoxy-1,4-imino-d-arabinitol	[no description available]	medium	1
purvalanol a	[no description available]	medium	2	purvalanol
melphalan	[no description available]	medium	2	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
isoliquiritigenin	[no description available]	medium	2	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
rauwolscine	[no description available]	medium	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate
gw9662	[no description available]	medium	2	benzamides
calmidazolium	[no description available]	medium	2	organic chloride salt	apoptosis inducer; calmodulin antagonist
tropisetron hydrochloride	[no description available]	medium	2
Reactive blue 2	[no description available]	medium	1	anthraquinone
5,6-dichloro-1-ethyl-1,3-dihydro-2h-benzimidazol-2-one	[no description available]	medium	1	dichlorobenzene
quinidine sulfate	[no description available]	medium	2
ipratropium bromide anhydrous	[no description available]	medium	1
methamilane methiodide	[no description available]	medium	1
pilocarpine nitrate	[no description available]	medium	1
r 59949	[no description available]	medium	4	diarylmethane
n(6)-cyclopentyladenosine	[no description available]	medium	2
methylatropine nitrate	[no description available]	medium	1
sb 366791	[no description available]	medium	2
3,3',4,5'-tetrahydroxystilbene	[no description available]	medium	3	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
bemesetron	[no description available]	medium	2
(S)-(-)-pindolol	[no description available]	medium	1	pindolol
levosulpiride	[no description available]	medium	1	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
4-fluorophenyl-L-alanine	[no description available]	medium	2	4-fluorophenylalanine; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid
urocanic acid	[no description available]	medium	1	urocanic acid	human metabolite
cotinine	[no description available]	medium	2	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
cinnarizine	[no description available]	medium	2	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac	[no description available]	medium	1	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
cysteine sulfinic acid	[no description available]	medium	1	organosulfinic acid; S-substituted L-cysteine	Escherichia coli metabolite; human metabolite; metabotropic glutamate receptor agonist; mouse metabolite
d-ap7	[no description available]	medium	1
(1R,2S)-tranylcypromine hydrochloride	[no description available]	medium	2	hydrochloride
tacrine hydrochloride	[no description available]	medium	2
4-bromotetramisole, oxalate (1:1), salt(s)-isomer	[no description available]	medium	2
3-hydroxybenzylhydrazine hydrochloride	[no description available]	medium	2
1-(3-chlorophenyl)biguanide hydrochloride	[no description available]	medium	2
4-chlorophenylalanine methyl ester, hydrochloride, (dl)-isomer	[no description available]	medium	1
capsazepine	[no description available]	medium	2	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
diphenyleneiodium chloride	[no description available]	medium	2	organic chloride salt	EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; G-protein-coupled receptor agonist
azetidine-2,4-dicarboxylic acid, (cis)-isomer	[no description available]	medium	1
tamoxifen citrate	[no description available]	medium	2	citrate salt	angiogenesis inhibitor; anticoronaviral agent
pimagedine hydrochloride	[no description available]	medium	1
Betaine Aldehyde Chloride	[no description available]	medium	1	quaternary ammonium salt
eskazine	[no description available]	medium	2
monastrol	[no description available]	medium	1	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor
u 0126	[no description available]	medium	5	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
4-diphenylacetoxy-n-methylpiperidine methiodide	[no description available]	medium	2	iodide salt; quaternary ammonium salt	cholinergic antagonist; muscarinic antagonist
1-(4-hydroxybenzyl)imidazole-2-thiol	[no description available]	medium	1
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide	[no description available]	medium	2
bp 897	[no description available]	medium	2	naphthalenecarboxamide
trequinsin hydrochloride	[no description available]	medium	2
neboglamine	[no description available]	medium	1
benzatropine methanesulfonate	[no description available]	medium	2
sb 203186	[no description available]	medium	1	indolyl carboxylic acid
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea	[no description available]	medium	2	1,2-thiazoles; indoles; ureas	receptor modulator; serotonergic antagonist
gw 7647	[no description available]	medium	2	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
ro 41-0960	[no description available]	medium	2
cgp 13501	[no description available]	medium	1	alkylbenzene
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide	[no description available]	medium	2
brl 15572	[no description available]	medium	2	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; secondary alcohol	geroprotector; serotonergic antagonist
mrs 1523	[no description available]	medium	2
or486	[no description available]	medium	1
fg 9041	[no description available]	medium	2	quinoxaline derivative
iik7	[no description available]	medium	1
sb 415286	[no description available]	medium	2	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
dm 235	[no description available]	medium	2
jhw 015	[no description available]	medium	2	indolecarboxamide
bw 723c86	[no description available]	medium	2	tryptamines
sc 560	[no description available]	medium	2	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
sc-19220	[no description available]	medium	1	aromatic ether
le 300	[no description available]	medium	2	indoles
ly 367265	[no description available]	medium	2	dihydropyridine; fluoroindole; tertiary amino compound; thiadiazoloquinoline	antidepressant; geroprotector; serotonergic antagonist; serotonin uptake inhibitor
diclofenac sodium	[no description available]	medium	1	organic sodium salt
cgp 7930	[no description available]	medium	2	alkylbenzene
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole	[no description available]	medium	2	phenols; pyrazoles	estrogen receptor agonist
sib 1757	[no description available]	medium	2
sphingosine	[no description available]	medium	2	sphing-4-enine	human metabolite; mouse metabolite
apigenin	[no description available]	medium	3	trihydroxyflavone	antineoplastic agent; metabolite
luteolin	[no description available]	medium	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
daphnetin	[no description available]	medium	3	hydroxycoumarin
genistein	[no description available]	medium	46	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
pulmicort	[no description available]	medium	2	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
timolol maleate	[no description available]	medium	2	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
brompheniramine maleate	[no description available]	medium	2	maleate salt	anti-allergic agent
chlorpheniramine maleate	[no description available]	medium	2	organic molecular entity
clemastine fumarate	[no description available]	medium	2	fumarate salt	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
methylergonovine maleate	[no description available]	medium	2	ergoline alkaloid	geroprotector
astaxanthine	[no description available]	medium	2	carotenol; carotenone	animal metabolite; anticoagulant; antioxidant; food colouring; plant metabolite
harman	[no description available]	medium	2	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
morin	[no description available]	medium	1	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin	[no description available]	medium	2	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
daidzein	[no description available]	medium	6	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
caffeic acid phenethyl ester	[no description available]	medium	2	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
rottlerin	[no description available]	medium	2	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
flupenthixol	[no description available]	medium	1	flupenthixol	dopaminergic antagonist
n-oleoyldopamine	[no description available]	medium	2	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide	TRPV1 agonist
pheniramine maleate	[no description available]	medium	2	organic molecular entity
tranilast	[no description available]	medium	2	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
trimipramine maleate	[no description available]	medium	2	maleate salt	antidepressant
isotretinoin	[no description available]	medium	2	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
xylometazoline hydrochloride	[no description available]	medium	2
flunarizine hydrochloride	[no description available]	medium	2	diarylmethane
ketotifen fumarate	[no description available]	medium	2	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
cis-flupenthixol dihydrochloride	[no description available]	medium	2	hydrochloride	geroprotector
n-arachidonylglycine	[no description available]	medium	2	fatty amide; N-acylglycine
n-oleoylethanolamine	[no description available]	medium	2	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
cyclosporine	[no description available]	medium	2	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
phenoxybenzamine hydrochloride	[no description available]	medium	2	organic molecular entity
phenylephrine hydrochloride	[no description available]	medium	1	hydrochloride
mepyramine maleate	[no description available]	medium	2
brefeldin a	[no description available]	medium	7	macrolide antibiotic	Penicillium metabolite
fenretinide	[no description available]	medium	2	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	[no description available]	medium	2	benzoic acids; naphthalenes; retinoid	antineoplastic agent; retinoic acid receptor agonist; teratogenic agent
l-2-(carboxypropyl)glycine	[no description available]	medium	1
4-aminocrotonic acid	[no description available]	medium	1
denopamine	[no description available]	medium	1	dimethoxybenzene
l 655,708	[no description available]	medium	2
ro 41-1049	[no description available]	medium	1
sb 200646a	[no description available]	medium	2
seglitide	[no description available]	medium	1
sib 1893	[no description available]	medium	1
su 6656	[no description available]	medium	4
tyrphostin ag 555	[no description available]	medium	3
tyrphostin ag-494	[no description available]	medium	2
tyrphostin b44	[no description available]	medium	3
ag-490	[no description available]	medium	4	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
semaxinib	[no description available]	medium	2	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
8-(3-chlorostyryl)caffeine	[no description available]	medium	2	monochlorobenzenes; trimethylxanthine	adenosine A2A receptor antagonist; EC 1.4.3.4 (monoamine oxidase) inhibitor
bay 11-7085	[no description available]	medium	2	benzenes; nitrile; sulfone	anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor
molsidomine	[no description available]	medium	1	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
diamide	[no description available]	medium	1	1,1'-azobis(N,N-dimethylformamide)
nomifensine maleate	[no description available]	medium	2
nalbuphine hydrochloride	[no description available]	medium	2	hydrochloride
isoalloxazine	[no description available]	medium	1	benzo[g]pteridine-2,4-dione
vinblastine sulfate	[no description available]	medium	2
n-methylscopolamine bromide	[no description available]	medium	1
dextromethorphan hydrobromide	[no description available]	medium	2	hydrate; hydrobromide
naloxone hydrochloride	[no description available]	medium	1	hydrochloride	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
s-trans,trans-farnesylthiosalicylic acid	[no description available]	medium	2	sesquiterpenoid
sulindac sulfone	[no description available]	medium	1	monocarboxylic acid; organofluorine compound; sulfone	apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
naltrexone hydrochloride	[no description available]	medium	2	hydrochloride	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
guanabenz acetate	[no description available]	medium	2	dichlorobenzene	geroprotector
nylidrin hydrochloride	[no description available]	medium	2	alkylbenzene
triprolidine hydrochloride anhydrous	[no description available]	medium	2	hydrochloride	H1-receptor antagonist
famotidine	[no description available]	medium	1	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
fenoterol	[no description available]	medium	1	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
tiapridex	[no description available]	medium	1	benzamides
quipazine maleate	[no description available]	medium	2
n-(2-aminoethyl)-4-chlorobenzamide hydrochloride	[no description available]	medium	1
tulobuterol hydrochloride	[no description available]	medium	2	organic molecular entity
hp 029	[no description available]	medium	2
n,n,n-trimethyl-1-(4-stilbenoxy)-2-propylammonium iodide	[no description available]	medium	1
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one	[no description available]	medium	3	naphthalenes
nf023	[no description available]	medium	1
nf 449	[no description available]	medium	2
7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine	[no description available]	medium	2
gr 46611	[no description available]	medium	1
diacetylmonoxime	[no description available]	medium	1
homatropine hydrobromide, (endo-(+-)-isomer)	[no description available]	medium	2
vancomycin hydrochloride	[no description available]	medium	1
moxisylyte hydrochloride	[no description available]	medium	1	monoterpenoid
dizocilpine maleate	[no description available]	medium	2	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
beta-aminopropionitrile fumarate	[no description available]	medium	1
flupirtine	[no description available]	medium	2
zimelidine hydrochloride	[no description available]	medium	2
pregna-4,17-diene-3,16-dione, (17z)-isomer	[no description available]	medium	2
su 4312	[no description available]	medium	2
gw 1929	[no description available]	medium	2	benzophenones
protriptyline hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant
n(4)-chloroacetylcytosine arabinoside	[no description available]	medium	1
n-(3-(cyclohexylidene-(1h-imidazol-4-ylmethyl))phenyl)ethanesulfonamide	[no description available]	medium	2
n-(4-amino-2-chlorophenyl)phthalimide	[no description available]	medium	1
cb 34	[no description available]	medium	1
b 43	[no description available]	medium	2	aromatic amine; aromatic ether; cyclopentanes; primary amino compound; pyrrolopyrimidine	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol	[no description available]	medium	1	aporphine alkaloid
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol	[no description available]	medium	1	aporphine alkaloid
3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane	[no description available]	medium	1
2-(3,3-diphenylpropylamino)acetamide	[no description available]	medium	2	diarylmethane
4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide	[no description available]	medium	1
gw2974	[no description available]	medium	1	pyridopyrimidine
l 162313	[no description available]	medium	2
l-165041	[no description available]	medium	1	aromatic ketone
mrs 1754	[no description available]	medium	1	oxopurine
s-nitroso-n-acetylpenicillamine	[no description available]	medium	1	nitroso compound; nitrosothio compound	nitric oxide donor; vasodilator agent
pd 404182	[no description available]	medium	1
sb 222200	[no description available]	medium	2	quinolines
dantrolene sodium	[no description available]	medium	2
cr 2945	[no description available]	medium	2
sb 218795	[no description available]	medium	2	quinolines
dihydroceramide	[no description available]	medium	1	N-acylsphinganine
epinephrine bitartrate	[no description available]	medium	2
bicuculline methobromide	[no description available]	medium	2
butylscopolammonium bromide	[no description available]	medium	1
butaclamol hydrochloride	[no description available]	medium	2
a 38503	[no description available]	medium	2
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide	[no description available]	medium	1
sk&f 89976-a	[no description available]	medium	1
cv 1808	[no description available]	medium	2	purine nucleoside
fluvoxamine maleate	[no description available]	medium	2	(trifluoromethyl)benzenes
naloxone benzoylhydrazone	[no description available]	medium	2
2-methyl-6-(phenylethynyl)pyridine hydrochloride	[no description available]	medium	2	hydrochloride	anxiolytic drug; metabotropic glutamate receptor antagonist
amiprilose	[no description available]	medium	1
(R)-fluoxetine hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant; serotonin uptake inhibitor
desmethylselegiline hydrochloride	[no description available]	medium	1
3-morpholino-sydnonimine monohydrochloride	[no description available]	medium	2
t 1032	[no description available]	medium	2
qx-314 bromide	[no description available]	medium	1
(S)-fluoxetine hydrochloride	[no description available]	medium	2	hydrochloride	antidepressant; serotonin uptake inhibitor
sr 59230a	[no description available]	medium	2
u 74389g	[no description available]	medium	2
1-(2-methoxyphenyl)piperazine hydrochloride	[no description available]	medium	2
y 27632, dihydrochloride, (4(r)-trans)-isomer	[no description available]	medium	2
noscapine hydrochloride	[no description available]	medium	2
a 77636	[no description available]	medium	2	hydrochloride	antiparkinson drug; dopamine agonist
cgp 20712a	[no description available]	medium	2
levodopa methyl ester hydrochloride	[no description available]	medium	2
benalfocin hydrochloride	[no description available]	medium	1
lu 19005	[no description available]	medium	2
benoxathian hydrochloride	[no description available]	medium	2
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid, (+)-isomer	[no description available]	medium	2
n-cyclopropyl adenosine-5'-carboxamide	[no description available]	medium	1
cefotaxime sodium	[no description available]	medium	1	organic sodium salt
calpain inhibitor iii	[no description available]	medium	2
GR 127935 hydrochloride	[no description available]	medium	2	hydrochloride	serotonergic antagonist
mrs 1845	[no description available]	medium	2
1-aminocyclopropane-1-carboxylic acid hydrochloride	[no description available]	medium	2
alaproclate hydrochloride	[no description available]	medium	2
ubenimex	[no description available]	medium	2	peptide
3-chloroalanine hydrochloride, (l-ala)-isomer	[no description available]	medium	1
dsp 4 hydrochloride	[no description available]	medium	2
calcimycin	[no description available]	medium	2	benzoxazole
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride	[no description available]	medium	2	hydrochloride	alpha-adrenergic antagonist
2-cyclooctyl-2-hydroxyethylamine hydrochloride	[no description available]	medium	2
cirazoline monohydrochloride	[no description available]	medium	2
adtn	[no description available]	medium	2
apocodeine hydrochloride, (r)-isomer	[no description available]	medium	2
Dihydro-beta-erythroidine hydrobromide	[no description available]	medium	1	indoles
lilly 78335	[no description available]	medium	2
efaroxan hydrochloride	[no description available]	medium	2
fenoldopam hydrobromide	[no description available]	medium	2
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	[no description available]	medium	2	hydrochloride	dopamine uptake inhibitor
guvacine hydrochloride	[no description available]	medium	1
7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide	[no description available]	medium	2
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer,	[no description available]	medium	2	organic molecular entity
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one	[no description available]	medium	2	hydrochloride	receptor modulator; serotonergic antagonist
4-iodoclonidine	[no description available]	medium	2
4-methylpyrazole monohydrochloride	[no description available]	medium	1
tele-methylhistamine	[no description available]	medium	1
alpha-methyltyrosine methyl ester, monohydrochloride	[no description available]	medium	2
octoclothepine maleate	[no description available]	medium	2
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride	[no description available]	medium	2
du 24565	[no description available]	medium	2
2-methoxyidazoxan hydrochloride	[no description available]	medium	2
ro 25-6981	[no description available]	medium	2
sk&f 77434	[no description available]	medium	2	hydrobromide	dopamine agonist; prodrug
3-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea	[no description available]	medium	2	organic heterotetracyclic compound; organonitrogen heterocyclic compound
demethylcantharidin	[no description available]	medium	2
atropine sulfate	[no description available]	medium	2
1-deoxynojirimycin hydrochloride	[no description available]	medium	1
win 62577	[no description available]	medium	2
quinine sulfate	[no description available]	medium	2	hydrate
quercetin	[no description available]	medium	2
rv 538, (r-(r,r))-isomer	[no description available]	medium	2
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1s-cis)-isomer	[no description available]	medium	2
valproate sodium	[no description available]	medium	1	organic sodium salt	geroprotector
u 63557a	[no description available]	medium	1
taurocholic acid, monosodium salt	[no description available]	medium	2	bile salt
cefmetazole sodium	[no description available]	medium	1	organic sodium salt	antimicrobial agent
fusidate sodium	[no description available]	medium	2
cephapirin sodium	[no description available]	medium	1	cephalosporin; organic sodium salt	antibacterial drug
sodium cephalothin	[no description available]	medium	1	organic sodium salt
cefazolin sodium	[no description available]	medium	2	organic sodium salt
5-hydroxydecanoic acid, monosodium salt	[no description available]	medium	1
ro13-9904	[no description available]	medium	1
phenytoin sodium	[no description available]	medium	1
cr 1409	[no description available]	medium	1
cortisol succinate, sodium salt	[no description available]	medium	2	organic molecular entity
piroxicam	[no description available]	medium	2	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
lfm a13	[no description available]	medium	2	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
l 701324	[no description available]	medium	1	quinolines
hispidin	[no description available]	medium	2	2-pyranones; catechols	antioxidant; EC 2.7.11.13 (protein kinase C) inhibitor; fungal metabolite
minocycline hydrochloride	[no description available]	medium	2
demeclocycline hydrochloride	[no description available]	medium	2
acyclovir	[no description available]	medium	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
sepiapterin	[no description available]	medium	1	sepiapterin
isoxanthopterin	[no description available]	medium	1	dihydroxypteridine
clozapine	[no description available]	medium	2	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
ganciclovir	[no description available]	medium	1	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
zaprinast	[no description available]	medium	2	triazolopyrimidines
allopurinol	[no description available]	medium	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
thiolactomycin	[no description available]	medium	1
2,4-diaminohypoxanthine	[no description available]	medium	1	hydroxypyrimidine
quazinone	[no description available]	medium	1
8-bromocyclic gmp, sodium salt	[no description available]	medium	2	organic sodium salt	muscle relaxant; protein kinase G agonist
ag-879	[no description available]	medium	2
ag 556	[no description available]	medium	1
pd 173074	[no description available]	medium	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
4,5,6,7-tetrabromo-2-azabenzimidazole	[no description available]	medium	1
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide	[no description available]	medium	1	naphthalenes; sulfonic acid derivative
ag 1295	[no description available]	medium	1	quinoxaline derivative	geroprotector
bisindolylmaleimide i	[no description available]	medium	7
bisindolylmaleimide iv	[no description available]	medium	1	indoles; maleimides
bohemine	[no description available]	medium	1	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
chelerythrine	[no description available]	medium	4	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
damnacanthal	[no description available]	medium	1	aldehyde; monohydroxyanthraquinone
n(6),n(6)-dimethyladenine	[no description available]	medium	2	tertiary amine
go 6976	[no description available]	medium	2	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
ha 1004	[no description available]	medium	1	isoquinolines
fasudil	[no description available]	medium	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
lavendustin a	[no description available]	medium	5	aromatic amine
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid	[no description available]	medium	1	aromatic amine
ml 9	[no description available]	medium	2	naphthalenes; sulfonic acid derivative
nu6102	[no description available]	medium	2
pd 153035	[no description available]	medium	1	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pd 169316	[no description available]	medium	2	imidazoles
1-NA-PP1	[no description available]	medium	1	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879	[no description available]	medium	2	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
sb 220025	[no description available]	medium	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063	[no description available]	medium	1	imidazoles
whi p180	[no description available]	medium	1
zm 336372	[no description available]	medium	1	benzamides
dichlororibofuranosylbenzimidazole	[no description available]	medium	1
1,4-naphthoquinone	[no description available]	medium	1	1,4-naphthoquinones
staurosporine	[no description available]	medium	1	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
arctigenin	[no description available]	medium	1	lignan
fascaplysine	[no description available]	medium	1
5-iodotubercidin	[no description available]	medium	1	organoiodine compound
imatinib mesylate	[no description available]	medium	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib	[no description available]	medium	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
vatalanib	[no description available]	medium	1	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
ruboxistaurin	[no description available]	medium	1
sb 203580	[no description available]	medium	2	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
erlotinib	[no description available]	medium	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
5-iodoindirubin-3'-monoxime	[no description available]	medium	1
2H-pyrazolo[4,3-b]quinoxalin-3-amine	[no description available]	medium	1	quinoxaline derivative
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea	[no description available]	medium	1
y 27632	[no description available]	medium	1	aromatic amide
h 1152	[no description available]	medium	1	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine	[no description available]	medium	1
6-bromoindirubin-3'-oxime	[no description available]	medium	2
h 89	[no description available]	medium	8	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione	[no description available]	medium	1	aminotoluene
tg 003	[no description available]	medium	2
thiourea	[no description available]	medium	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore
dasatinib	[no description available]	medium	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
gtp 14564	[no description available]	medium	1	pyrazoles; ring assembly
sb 218078	[no description available]	medium	1	indolocarbazole
alsterpaullone	[no description available]	medium	1	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
quercetin	[no description available]	medium	2	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
wedelolactone	[no description available]	medium	1	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
geldanamycin	[no description available]	medium	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
su 9516	[no description available]	medium	2
kn 93	[no description available]	medium	1	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
su 11248	[no description available]	medium	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
su 11652	[no description available]	medium	1	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one	[no description available]	medium	1	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
st 638	[no description available]	medium	1
su 1498	[no description available]	medium	3	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
monorden	[no description available]	medium	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
ml 3403	[no description available]	medium	1
d 4476	[no description available]	medium	1	imidazoles
GSK3-XIII	[no description available]	medium	1	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole	[no description available]	medium	1	aryl sulfide
aminopurvalanol a	[no description available]	medium	1	monochlorobenzenes; purvalanol	protein kinase inhibitor
cvt 313	[no description available]	medium	1
bibx 1382bs	[no description available]	medium	1	substituted aniline
sl 327	[no description available]	medium	1
tws 119	[no description available]	medium	1	pyrroles
krn 633	[no description available]	medium	1
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)	[no description available]	medium	2	sulfonamide
c 1368	[no description available]	medium	1
pq 401	[no description available]	medium	1	quinolines
jnj 10198409	[no description available]	medium	1
nu 7026	[no description available]	medium	1	organic heterotricyclic compound; organooxygen compound
pi103	[no description available]	medium	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
fr 180204	[no description available]	medium	1	pyrazoles; ring assembly
gw 2580	[no description available]	medium	1
hymenialdisine	[no description available]	medium	1
isogranulatimide	[no description available]	medium	1
debromohymenialdisine	[no description available]	medium	1
4-(1H-imidazol-1-ylmethyl)benzonitrile	[no description available]	medium	1	benzenes; nitrile
cgp 52411	[no description available]	medium	1	phthalimides	geroprotector; tyrosine kinase inhibitor
aa 861	[no description available]	medium	1	1,4-benzoquinones; acetylenic compound; primary alcohol	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor
bu 224	[no description available]	medium	1	quinolines
chloroquine	[no description available]	medium	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
2-bromoergocryptine mesylate	[no description available]	medium	1	methanesulfonate salt	antiparkinson drug
salmeterol xinafoate	[no description available]	medium	1	naphthoic acid
finasteride	[no description available]	medium	1	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
eliprodil	[no description available]	medium	1	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
sertraline hydrochloride	[no description available]	medium	1	hydrochloride	antidepressant; serotonin uptake inhibitor
opipramol hydrochloride	[no description available]	medium	1
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole	[no description available]	medium	2	ether; imidazoles; monomethoxybenzene	TRP channel blocker
u 78517f	[no description available]	medium	1
mk 912	[no description available]	medium	1
sk&f 86466	[no description available]	medium	1	benzazepine
w 7	[no description available]	medium	1
4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine	[no description available]	medium	1
dizocilpine	[no description available]	medium	1	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
phenylthiazolylthiourea	[no description available]	medium	1
(2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine)	[no description available]	medium	1	benzimidazoles
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene	[no description available]	medium	1	C-nitro compound; sulfonamide; toluenes	bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector
quinine	[no description available]	medium	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
l 663536	[no description available]	medium	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
ml 10302	[no description available]	medium	1
bw b70c	[no description available]	medium	1	aromatic ether; hydroxamic acid; organofluorine compound; ureas	EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
mg 624	[no description available]	medium	1
5-(4-phenylbutoxy)psoralen	[no description available]	medium	1	aromatic ether; benzenes; psoralens	geroprotector; immunosuppressive agent; potassium channel blocker
bisoprolol, fumarate (1:1) salt	[no description available]	medium	1
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate hydrochloride	[no description available]	medium	1
ro 8-4304	[no description available]	medium	1
sb 203186	[no description available]	medium	1
2-hydroxyapomorphine, (r)-isomer	[no description available]	medium	1
N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide	[no description available]	medium	1	hydrobromide	dopamine agonist; prodrug
7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine	[no description available]	medium	1	pyrroles
vanadates	[no description available]	medium	13	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
concanamycin a	[no description available]	medium	2	carbamate ester; concanamycin	antifungal agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; metabolite
tyrosine	[no description available]	medium	17	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
salicylic acid	[no description available]	medium	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
lactic acid	[no description available]	medium	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
glutamic acid	[no description available]	medium	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
abscisic acid	[no description available]	medium	1	2-trans-abscisic acid
w 7	[no description available]	medium	2
calmidazolium	[no description available]	medium	1	imidazolium ion	apoptosis inducer; calmodulin antagonist
2-aminoethoxydiphenyl borate	[no description available]	medium	1	organoboron compound; primary amino compound	calcium channel blocker; IP3 receptor antagonist; potassium channel opener
fluorides	[no description available]	medium	1	halide anion; monoatomic fluorine
staurosporine	[no description available]	medium	6	ammonium ion derivative
okadaic acid	[no description available]	medium	1	ketal
tyrphostin ag 1024	[no description available]	medium	1	alkylbenzene
transforming growth factor alpha	[no description available]	medium	3
herbimycin	[no description available]	medium	3	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
brimonidine tartrate	[no description available]	medium	1
rtki cpd	[no description available]	medium	3
quinoxalines	[no description available]	medium	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
quinazolines	[no description available]	medium	4	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
piperidines	[no description available]	medium	2
ucn 1028 c	[no description available]	medium	7
bucladesine	[no description available]	medium	2	3',5'-cyclic purine nucleotide
n-formylmethionine leucyl-phenylalanine	[no description available]	medium	4	tripeptide
interleukin-8	[no description available]	medium	2
cromakalim	[no description available]	medium	1
geldanamycin	[no description available]	medium	1
aldosterone	[no description available]	medium	3	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
potassium chloride	[no description available]	medium	6	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
propranolol	[no description available]	medium	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
d 609	[no description available]	medium	2
fura-2	[no description available]	medium	1
methoxamine	[no description available]	medium	1	amphetamines	alpha-adrenergic agonist; antihypotensive agent
nitric acid	[no description available]	medium	1	nitrogen oxoacid	protic solvent; reagent
safingol	[no description available]	medium	1	amino alcohol
fingolimod hydrochloride	[no description available]	medium	1	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
n,n-dimethylsphingenine	[no description available]	medium	1	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
vasoactive intestinal peptide	[no description available]	medium	2
sphingosine kinase	[no description available]	medium	1
ng-nitroarginine methyl ester	[no description available]	medium	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
endothelin-1	[no description available]	medium	5
cyclic gmp	[no description available]	medium	2	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid	[no description available]	medium	2
cytochalasin d	[no description available]	medium	1
2,2,5,7,8-pentamethyl-1-hydroxychroman	[no description available]	medium	1
1-(5-isoquinolinesulfonyl)-2-methylpiperazine	[no description available]	medium	3	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide	[no description available]	medium	1	isoquinolines; sulfonamide
chlorine	[no description available]	medium	3	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
glycerophosphoinositol 4,5-bisphosphate	[no description available]	medium	2
manganese	[no description available]	medium	1	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
phosphotyrosine	[no description available]	medium	9	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
epidermal growth factor	[no description available]	medium	12
thymidine	[no description available]	medium	4	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
myelin basic protein	[no description available]	medium	1
pn 202-791	[no description available]	medium	1	benzoxadiazole; isopropyl ester
oxadiazoles	[no description available]	medium	1
8-bromo cyclic adenosine monophosphate	[no description available]	medium	3	3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound	antidepressant; protein kinase agonist
transforming growth factor beta	[no description available]	medium	1
ro 31-8220	[no description available]	medium	3	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
angiotensin ii	[no description available]	medium	6	amino acid zwitterion; angiotensin II	human metabolite
1-oleoyl-2-acetylglycerol	[no description available]	medium	1	1,2-diglyceride
dinoprostone	[no description available]	medium	2	prostaglandins E	human metabolite; mouse metabolite; oxytocic
phorbol 12,13-dibutyrate	[no description available]	medium	1	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
eicosapentaenoic acid	[no description available]	medium	1	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
1-hexadecyl-2-acetyl-glycero-3-phosphocholine	[no description available]	medium	1	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent
nicotine	[no description available]	medium	2	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fluo-3	[no description available]	medium	1	xanthene dye	fluorochrome
xanthenes	[no description available]	medium	1	xanthene
digitonin	[no description available]	medium	1
atropine	[no description available]	medium	1
guanosine 5'-o-(3-thiotriphosphate)	[no description available]	medium	1	nucleoside triphosphate analogue
pervanadate	[no description available]	medium	2
bq 3020	[no description available]	medium	1
s6c sarafotoxin	[no description available]	medium	2
bq 123	[no description available]	medium	1	cyclic peptide
irl 1620	[no description available]	medium	1
thromboxane a2	[no description available]	medium	1	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
leucine	[no description available]	medium	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
hydrogen	[no description available]	medium	1	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
substance p	[no description available]	medium	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
mercaptoethanol	[no description available]	medium	1	alkanethiol; primary alcohol	geroprotector
vitamin k semiquinone radical	[no description available]	medium	1
naphthoquinones	[no description available]	medium	1
arsenic	[no description available]	medium	1	metalloid atom; pnictogen	micronutrient
oxophenylarsine	[no description available]	medium	1	arsine oxides	antineoplastic agent; apoptosis inducer; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
bradykinin	[no description available]	medium	3	oligopeptide	human blood serum metabolite; vasodilator agent
amitrole	[no description available]	medium	1	aromatic amine; triazoles	carotenoid biosynthesis inhibitor; EC 1.11.1.6 (catalase) inhibitor; herbicide
suramin	[no description available]	medium	1	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
cyclosporine	[no description available]	medium	1
betaine	[no description available]	medium	1	amino-acid betaine; glycine derivative	fundamental metabolite
inositol	[no description available]	medium	1	cyclitol; hexol
tacrolimus	[no description available]	medium	1	macrolide lactam	bacterial metabolite; immunosuppressive agent
cadmium	[no description available]	medium	1	cadmium molecular entity; zinc group element atom
p-methoxy-n-methylphenethylamine	[no description available]	medium	1	aromatic ether; secondary amino compound	metabolite
staurosporine aglycone	[no description available]	medium	1
9,10-dimethyl-1,2-benzanthracene	[no description available]	medium	1	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
inositol 1,4,5-trisphosphate	[no description available]	medium	2	myo-inositol trisphosphate	mouse metabolite
gallic acid	[no description available]	medium	2	trihydroxybenzoic acid	antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite
guanosine 5'-o-(2-thiodiphosphate)	[no description available]	medium	1	nucleoside diphosphate analogue
sevoflurane	[no description available]	medium	1	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
anthranilic acid	[no description available]	medium	1	aminobenzoic acid	human metabolite; mouse metabolite
guanosine diphosphate	[no description available]	medium	1	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
deoxyglucose	[no description available]	medium	1
enalaprilat anhydrous	[no description available]	medium	2	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
icatibant	[no description available]	medium	1
adenine	[no description available]	medium	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
9-(tetrahydro-2-furyl)-adenine	[no description available]	medium	1
saralasin	[no description available]	medium	1	oligopeptide
barium	[no description available]	medium	1	alkaline earth metal atom; elemental barium
1,4-dihydropyridine	[no description available]	medium	1
8-bromocyclic gmp	[no description available]	medium	1	3',5'-cyclic purine nucleotide; organobromine compound	muscle relaxant; protein kinase G agonist
dihydropyridines	[no description available]	medium	1
arachidonic acid	[no description available]	medium	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
cholecystokinin	[no description available]	medium	1
protocatechuic acid	[no description available]	low	0	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite
2,3-dihydroxybiphenyl	[no description available]	low	0	catechols; hydroxybiphenyls
sk&f 77434	[no description available]	low	0	benzazepine; catechols; tertiary amino compound	dopamine agonist
6-fluoronorepinephrine	[no description available]	low	0	catechols
benserazide	[no description available]	low	0	carbohydrazide; catechols; primary alcohol; primary amino compound	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
caffeic acid	[no description available]	low	0	catechols; hydroxycinnamic acid	antioxidant; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
isoproterenol	[no description available]	low	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
4-[(1S)-1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol	[no description available]	low	0	catechols
3-methoxycatechol	[no description available]	low	0	aromatic ether; catechols	G-protein-coupled receptor agonist
3,4-dihydroxyacetophenone	[no description available]	low	0	acetophenones; catechols; dihydroxyacetophenone	metabolite
ethylnorepinephrine	[no description available]	low	0	catechols
3-o-methylgallic acid	[no description available]	low	0	benzoic acids; catechols
colterol	[no description available]	low	0	catechols; ethanolamines; secondary alcohol; secondary amino compound; triol	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent
4-bromocatechol	[no description available]	low	0	catechols
enterobactin	[no description available]	low	0	catechols; crown compound; macrotriolide; polyphenol	bacterial metabolite; siderophore
carbidopa	[no description available]	low	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
salvin	[no description available]	low	0	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite
3-pentadecacatechol	[no description available]	low	0	catechols	allergen
4-ethylcatechol	[no description available]	low	0	catechols
brazilin	[no description available]	low	0	catechols; organic heterotetracyclic compound; tertiary alcohol	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; apoptosis inducer; biological pigment; hepatoprotective agent; histological dye; NF-kappaB inhibitor; plant metabolite
ethyl protocatechuate	[no description available]	low	0	catechols; ethyl ester	antibacterial agent; antioxidant; apoptosis inducer; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; plant metabolite
lanosol	[no description available]	low	0	catechols
3,4-dihydroxyphenylethanol	[no description available]	low	0	catechols; primary alcohol	antineoplastic agent; antioxidant; metabolite
3,4-dihydroxymandelic acid	[no description available]	low	0	2-hydroxy monocarboxylic acid; catechols	antioxidant; drug metabolite; human metabolite; mouse metabolite
3,4-dihydroxyphenylglycol	[no description available]	low	0	catechols; tetrol	metabolite; mouse metabolite
3,4-dihydroxybenzylamine	[no description available]	low	0	catechols
droxidopa	[no description available]	low	0	catechols; L-tyrosine derivative	antihypertensive agent; prodrug; vasoconstrictor agent
n-acetyldopamine	[no description available]	low	0	acetamides; catechols; N-(fatty acyl)-dopamine; secondary carboxamide	human urinary metabolite; marine metabolite
3,4-dihydroxyphenylacetaldehyde	[no description available]	low	0	alpha-CH2-containing aldehyde; catechols; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite
3-heptadecylcatechol	[no description available]	low	0	catechols
beta-lipotropin, gln(9)-	[no description available]	low	0	catechols; crown compound; macrocyclic lactone	bacterial metabolite; metabolite
protosappanin a	[no description available]	low	0	catechols	metabolite
chrysobactin	[no description available]	low	0	catechols; dipeptide; monocarboxylic acid; primary alcohol; primary amino compound	bacterial metabolite; siderophore
sk&f 83959	[no description available]	low	0	benzazepine; catechols; organochlorine compound; tertiary amino compound	dopamine agonist
3,4-dihydroxyphenylglycolaldehyde	[no description available]	low	0	catechols; hydroxyaldehyde	human metabolite; mouse metabolite; neurotoxin
a 3253	[no description available]	low	0	catechols
2-s-cysteinyldopa	[no description available]	low	0	amino dicarboxylic acid; aryl sulfide; catechols; diamine; L-tyrosine derivative; S-conjugate; S-organyl-L-cysteine	human urinary metabolite
4-fluorocatechol	[no description available]	low	0	catechols
n(beta)-alanyldopamine	[no description available]	low	0	catechols; primary amino compound; secondary carboxamide
3-hydroxyterphenyllin	[no description available]	low	0	catechols; dimethoxybenzene; para-terphenyl	Aspergillus metabolite
methyl 3,4-dihydroxybenzoate	[no description available]	low	0	catechols; methyl ester	antioxidant; neuroprotective agent; plant metabolite
norbelladine	[no description available]	low	0	catechols; phenethylamine alkaloid; polyphenol; secondary amino compound	plant metabolite
rimiterol	[no description available]	low	0	catechols
3,4-dihydroxyphenyllactic acid	[no description available]	low	0	2-hydroxy monocarboxylic acid; catechols
2-hydroxyestrone	[no description available]	low	0	2-hydroxy steroid; catechols	human metabolite
tolcapone	[no description available]	low	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
entacapone	[no description available]	low	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
oleuropein	[no description available]	low	0	beta-D-glucoside; catechols; diester; methyl ester; pyrans; secoiridoid glycoside	anti-inflammatory agent; antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; NF-kappaB inhibitor; nutraceutical; plant metabolite; radical scavenger
5-o-caffeoylshikimic acid	[no description available]	low	0	alpha,beta-unsaturated monocarboxylic acid; carboxylic ester; catechols; cyclohexenecarboxylic acid	plant metabolite
acteoside	[no description available]	low	0	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite
ellagic acid	[no description available]	low	0	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
arachidonyl dopamine	[no description available]	low	0	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide
sappanchalcone	[no description available]	low	0	catechols; chalcones; monomethoxybenzene	anti-allergic agent; anti-inflammatory agent; antioxidant; metabolite
tetrahydroxycurcumin	[no description available]	low	0	beta-diketone; catechols; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; neuroprotective agent; plant metabolite
2',3,4-trihydroxychalcone	[no description available]	low	0	catechols; chalcones
3',4'-dihydroxyaurone	[no description available]	low	0	catechols; hydroxyaurone	EC 3.5.1.98 (histone deacetylase) inhibitor
thunberginol f	[no description available]	low	0	catechols; gamma-lactone; isobenzofuranone	metabolite; plant metabolite
salvianolic acid B	[no description available]	low	0	1-benzofurans; catechols; dicarboxylic acid; enoate ester; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; apoptosis inducer; autophagy inhibitor; cardioprotective agent; hepatoprotective agent; hypoglycemic agent; neuroprotective agent; osteogenesis regulator; plant metabolite
a 77636	[no description available]	low	0	adamantanes; catechols; isochromenes; primary amino compound	antiparkinson drug; dopamine agonist
altenusin	[no description available]	low	0	aromatic ether; carboxybiphenyl; catechols; hydroxybiphenyls; polyphenol	antifungal agent; fungal metabolite
4-hydroxyestrone	[no description available]	low	0	17-oxo steroid; 3-hydroxy steroid; 4-hydroxy steroid; catechols; phenolic steroid	carcinogenic agent; estrogen; human urinary metabolite
n-caffeoyltyramine	[no description available]	low	0	catechols
11-hydroxysugiol	[no description available]	low	0	abietane diterpenoid; carbotricyclic compound; catechols; cyclic terpene ketone; meroterpenoid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
myxochelin b	[no description available]	low	0	benzamides; catechols	bacterial metabolite; siderophore
aspalathin	[no description available]	low	0	C-glycosyl compound; catechols; dihydrochalcones; polyketide; polyphenol	antioxidant; EC 1.17.3.2 (xanthine oxidase) inhibitor; hypoglycemic agent; plant metabolite
dihydro-n-caffeoyltyramine	[no description available]	low	0	catechols
violaceol II	[no description available]	low	0	aromatic ether; catechols; resorcinols	mycotoxin
1-(3,4-dihydroxyphenyl)-2-thiocyanate-ethanone	[no description available]	low	0	aromatic ketone; catechols; thiocyanates
vanchrobactin	[no description available]	low	0	catechols; dipeptide; guanidines; monocarboxylic acid; primary alcohol; triol	bacterial metabolite; marine metabolite; siderophore
oleuropein aglycone	[no description available]	low	0	catechols; diester; lactol; methyl ester; pyrans; secoiridoid	anti-inflammatory agent; antioxidant; mTOR inhibitor; neuroprotective agent; plant metabolite; TRPA1 channel agonist
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide	[no description available]	low	0	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5	2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46	2019
Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles. Circulation research, Feb-16, Volume: 88, Issue: 3	2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Modulations of shear stress-induced contractile responses and agonist-induced vasodilation in hypercholesterolemic rats. Atherosclerosis, Volume: 175, Issue: 1	2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

tyrphostin a23

Description

Cross-References

Synonyms (109)

Drug Classes (1)

Protein Targets (102)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (248)

Molecular Functions (57)

Ceullar Components (64)

Bioassays (137)

Research

Studies (158)

Study Types

Research Highlights

Pharmacokinetics (1)

Bioavailability (3)

Dosage (1)

Condition	Relationship Strength	Studies
Abnormalities, Autosome	low	1
Abnormalities, Chromosomal	low	1
Abnormalities, Chromosome	low	1
Acidosis	low	1
Acute Respiratory Distress Syndrome	low	1
Adult Respiratory Distress Syndrome	low	1
Amyloid Deposits	low	1
Amyloid Plaques	low	1
Anemia, Fanconi	low	1
Anterior Circulation Transient Ischemic Attack	low	1
ARDS, Human	low	1
Autosome Abnormalities	low	1
Benign Neoplasms	low	1
Bladder Cancer	low	1
Bladder Neoplasms	low	1
Bladder Tumors	low	1
Blood Pressure, High	low	2
Brain Stem Ischemia, Transient	low	1
Brain Stem Transient Ischemic Attack	low	1
Brain TIA	low	1
Brainstem Ischemia, Transient	low	1
Brainstem Transient Ischemic Attack	low	1
Cancer	low	1
Cancer of Bladder	low	1
Cancer of Kidney	low	1
Cancer of Liver	low	1
Cancer of Pancreas	low	1
Cancer of Pituitary	low	1
Cancer of Prostate	low	1
Cancer of the Bladder	low	1
Cancer of the Kidney	low	1
Cancer of the Liver	low	1
Cancer of the Pancreas	low	1
Cancer of the Pituitary	low	1
Cancer of the Prostate	low	1
Cancer, Hepatocellular	low	1
Capillary Leak Syndrome	low	1
Carcinoma, Epidermoid	low	2
Carcinoma, Hepatocellular	low	1
Carcinoma, Planocellular	low	2
Carcinoma, Squamous	low	2
Carcinoma, Squamous Cell	low	2
Carotid Circulation Transient Ischemic Attack	low	1
Cerebral Ischemia, Transient	low	1
Chromosomal Aberrations	low	1
Chromosome Aberrations	low	1
Chromosome Abnormalities	low	1
Clarkson Disease	low	1
Cleft Lip	low	1
Cleft Palate	low	1
Cleft Palate, Isolated	low	1
Clinical Capillary Leak Syndrome	low	1
Congenital Zika Syndrome	low	1
Congenital Zika Virus Infection	low	1
Contact Dermatitis	low	1
Crescendo Transient Ischemic Attacks	low	1
Cystic Fibrosis	low	1
Cystic Fibrosis of Pancreas	low	1
Cytogenetic Aberrations	low	1
Cytogenetic Abnormalities	low	1
Dermatitis Venenata	low	1
Dermatitis, Contact	low	1
Disease Models, Animal	low	2
Eczema, Contact	low	1
Elevated Cholesterol	low	1
Esophageal Diseases	low	1
Fanconi Anemia	low	1
Fanconi Hypoplastic Anemia	low	1
Fanconi Pancytopenia	low	1
Fanconi Panmyelopathy	low	1
Fanconi's Anemia	low	1
Fever, Zika	low	1
Fibrocystic Disease of Pancreas	low	1
Fibrosarcoma	low	1
Harelip	low	1
Hepatic Cancer	low	1
Hepatic Neoplasms	low	1
Hepatocellular Cancer	low	1
Hepatocellular Carcinoma	low	1
Hepatoma	low	1
High Cholesterol Levels	low	1
Hypercholesteremia	low	1
Hypercholesterolemia	low	1
Hyperplasia	low	1
Hypersensitivity, Contact	low	1
Hypertension	low	2
Inflammation	low	2
Innate Inflammatory Response	low	2
Ischemic Attack, Transient	low	1
Itching	low	1
Kidney Cancer	low	1
Kidney Neoplasms	low	1
Liver Cancer	low	1
Liver Cancer, Adult	low	1
Liver Cell Carcinoma	low	1
Liver Cell Carcinoma, Adult	low	1
Liver Neoplasms	low	1
Malaria, Falciparum	low	1
Malignancy	low	1
Malignant Neoplasms	low	1
Malignant Tumor of Urinary Bladder	low	1
Metabolic Acidosis	low	1
Metastase	low	1
Metastases, Neoplasm	low	1
Metastasis	low	1
Metastasis, Neoplasm	low	1
Mucoviscidosis	low	1
Muscle Contraction	low	5
Neoplasia	low	1
Neoplasm	low	1
Neoplasm Metastases	low	1
Neoplasm Metastasis	low	1
Neoplasms	low	1
Neoplasms, Benign	low	1
Neoplasms, Bladder	low	1
Neoplasms, Hepatic	low	1
Neoplasms, Kidney	low	1
Neoplasms, Liver	low	1
Neoplasms, Pancreatic	low	1
Neoplasms, Prostate	low	1
Neoplasms, Prostatic	low	1
Nerve Degeneration	low	1
Neuritic Plaques	low	1
Neuron Degeneration	low	1
Palmoplantaris Pustulosis	low	2
Pancreas Cancer	low	1
Pancreas Neoplasms	low	1
Pancreatic Cancer	low	1
Pancreatic Cystic Fibrosis	low	1
Pancreatic Neoplasms	low	1
Pediatric Respiratory Distress Syndrome	low	1
Pituitary Adenoma	low	1
Pituitary Cancer	low	1
Pituitary Carcinoma	low	1
Pituitary Neoplasms	low	1
Pituitary Tumors	low	1
Plaque, Amyloid	low	1
Plaques, Amyloid	low	1
Plasmodium falciparum Malaria	low	1
Posterior Circulation Transient Ischemic Attack	low	1
Pregnancy	low	2
Prostate Cancer	low	1
Prostate Neoplasms	low	1
Prostatic Cancer	low	1
Prostatic Neoplasms	low	1
Pruritis	low	1
Pruritus	low	1
Psoriasis	low	2
Pulmonary Cystic Fibrosis	low	1
Pustular Psoriasis of Palms and Soles	low	2
Pustulosis of Palms and Soles	low	2
Pustulosis Palmaris et Plantaris	low	2
Renal Cancer	low	1
Renal Neoplasms	low	1
Respiratory Distress Syndrome	low	1
Respiratory Distress Syndrome, Acute	low	1
Respiratory Distress Syndrome, Adult	low	1
Respiratory Distress Syndrome, Pediatric	low	1
Sarcoma, Synovial	low	1
Senile Plaques	low	1
Sensitivity and Specificity	low	1
Sensitivity, Contact	low	1
Shock Lung	low	1
Squamous Cell Carcinoma	low	2
Synovioma	low	1
Systemic Capillary Leak Syndrome	low	1
TIA (Transient Ischemic Attack)	low	1
Transient Ischemic Attack	low	1
Transient Ischemic Attack, Anterior Circulation	low	1
Transient Ischemic Attack, Brain Stem	low	1
Transient Ischemic Attack, Brainstem	low	1
Transient Ischemic Attack, Carotid Circulation	low	1
Transient Ischemic Attack, Posterior Circulation	low	1
Transient Ischemic Attack, Vertebrobasilar Circulation	low	1
Transient Ischemic Attacks, Crescendo	low	1
Tumors	low	1
Urinary Bladder Cancer	low	1
Urinary Bladder Neoplasms	low	1
Vertebrobasilar Circulation Transient Ischemic Attack	low	1
Zika Fever	low	1
Zika Virus Disease	low	1
Zika Virus Infection	low	1
ZikV Infection	low	1

Article	Year
Swelling-activated K+ efflux and regulatory volume decrease efficiency in human bronchial epithelial cells. The Journal of membrane biology, Volume: 214, Issue: 1	2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

tyrphostin a23

Description

Cross-References

Synonyms (109)

Drug Classes (1)

Protein Targets (102)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (248)

Molecular Functions (57)

Ceullar Components (64)

Bioassays (137)

Research

Studies (158)

Study Types

Related Drugs (1,249)

Related Conditions (183)

Research Highlights

Pharmacokinetics (1)

Bioavailability (3)

Dosage (1)